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Abstract 
Dysregulation of the mTORC1 pathway has been linked to several human 
diseases, particularly cancer; but attempts to target mTORC1 directly have been mostly 
unsuccessful due to observed drug resistance. Most mechanisms of resistance result in 
dysregulation of cap-dependent translation, and thus, perpetuation of a cancerous 
phenotype. eIF4E is a downstream effector of mTORC1 signaling and the rate-limiting 
factor in cap-dependent translation. Cellular eIF4E activity is regulated by the 4E-BPs, 
which act as gatekeepers of eIF4E by binding and sequestering the protein to prevent 
cap-dependent translation initiation. Hyperphosphorylation of the 4E-BPs by mTORC1 
decreases their affinity for eIF4E and allows it to bind eIF4G and ultimately initiate cap-
dependent translation of oncogenes, growth factors, and survival factors. The aim of 
this work is to develop an inhibitor of the eIF4E–eIF4G PPI using eIF4G and 4E-BP1 
peptides as models. 
eIF4G and 4E-BP share the same binding site on the surface of eIF4E. Both 
proteins are intrinsically disordered or have intrinsically disordered regions in solution 
but adopt a short helix upon binding to eIF4E.  Peptide versions of each of the proteins 
which encompass the crystalized binding sites were purchased and analyzed by CD 
and SPR.  It was found that, while both peptides share a near identical binding motif, 
their structures in solution and their kinetics of binding are quite different.  The 4E-BP 
peptide is somewhat helical in solution, demonstrates little temperature dependence of 
xiv 
 
its on-rate (ka), off-rate (kd), and binding constant (KD), and has a slower kd and stronger 
Kd with increasing ionic strength.  Conversely, the eIF4G peptide is not helical in 
solution, has a faster kd with increasing temperature, and a weaker Kd with increasing 
ionic strength. The ka of eIF4G was faster under all circumstances than the ka of 4E-BP, 
but the 4E-BP peptide had a much slower kd and therefore a stronger KD.  Taken 
together, this data indicates that while eIF4G associates much more quickly with eIF4E, 
its binding motif is much less stable.  We hypothesize that the differences are due to 
different binding mechanisms adopted by each peptide, in which eIF4G favors an 
induced fit binding mode, but 4E-BP likely adopts a combination of induced fit and 
conformational selection. 
We next synthesized hydrocarbon stapled peptide based on the eIF4G and 4E-
BP peptide sequences.  While the helicity of the 4E-BP stapled peptide (HCS 4E-BP1) 
was much higher than the linear peptide, the eIF4G stapled peptide (HCS eIF4G) was 
still barely helical in solution.  Additionally, the binding constant for the 4E-BP peptide 
improved from 26 nM to 4 nM upon stapling, whereas the binding constant for the 
eIF4G peptide lost activity (29 nM to 90 nM).  The constraint of the staple appears to be 
preventing its preferred association mechanism, and its loss in affinity is entirely due to 
a decreased ka.  We hypothesize that this is because HCS eIF4G still favors an induced 
fit binding mechanism.  We also analyzed linear and stapled versions of sTIP-04, an 
eIF4E binding stapled peptide from the literature.1  This peptide is based on the eIF4G 
sequence, but has been mutated to favor the bound structure.  Interestingly, the linear 
peptide behaved very similarly to the linear eIF4G peptide at different temperatures, but 
behaved more similarly to the linear 4E-BP peptide at different salt concentrations.  The 
xv 
 
stapled peptide, sTIP-04, behaved similarly to HCS 4E-BP1.  We suspect that this 
sequence is able to bind through multiple mechanisms, and therefore its association 
rate is less penalized by the constraint of the staple. 
While the hydrocarbon stapled 4E-BP peptide demonstrated excellent activity in 
vitro and in cell based assays, it still suffered from poor solubility, poor reproducibility, 
and a tendency to aggregate.  Thus, efforts were made to construct a stapled peptide 
with better properties in solution.  While modifications to the peptide side chains did not 
improve the peptides in vitro activity, changing the staple type from hydrocarbon to a 
lactam staple of similar length significantly improved solubility and behavior while 
maintaining activity.  This new lead peptide has similar structural properties as HCS 4E-
BP1 (lactam staple = 40% helical, HCS = 44% helical) and similar affinity for eIF4E 
(lactam staple = 2 nM, HCS = 4 nM).  Additionally, the lactam stapled peptide is highly 
cell permeable, as demonstrated with CAPA performed by the Kritzer lab.  We solved 
the NMR structure of this peptide in solution and found that it forms a compact structure 
in phosphate buffer and hypothesize that this structure is critical for cell penetration. 
Future directions on this project will focus on optimizing this peptide for use as a 
probe for the eIF4E–eIF4G PPI.  First, there are two unstable residues (methionine and 
cysteine) which have a tendency to oxidize.  Further work will be done to replace these 
residues to improve the shelf life of the peptide.  Next, we are currently getting 
information about the stability of the peptide when exposed to proteases and other 
metabolizing enzymes in vitro.  This information will be used to block the most 
metabolically labile sites to improve the half-life of the peptide in vivo.  We will also 
further investigate the effects of staple length, type, and orientation on the activity and 
xvi 
 
cell penetrability of the peptide.  Finally, we will explore options for good models to use 
the optimized peptide to validate the eIF4E–eIF4G PPI in vivo. 
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Chapter 1 
Cap-Dependent Translation and its Relevance to Disease 
 
1.1 The PI3K pathway and its relation to cancer 
 Cancerous cells increase their evolutionary advantage over healthy cells by 
hijacking normally innocent cell processes and manipulating them for more insidious 
purposes.  DNA mutations, dysregulation of transcription, post transcriptional and 
translational modifications, and altered translation are all used to dysregulate the 
general order of the cell to promote excessive growth, avoid apoptosis, promote 
angiogenesis, and ultimately metastasize.  Traditional chemotherapeutic drugs focus on 
targeting the excessive growth of cancer cells using DNA binding and damaging agents.  
However, these treatments are harmful to fast replicating healthy cells and many 
cancers develop resistance mechanisms, limiting the effectiveness of these treatments.  
This has led to the search for other targets which are dysregulated in cancer cells in 
hopes of finding a more effective treatment.   
One such pathway which is highly mutated in cancer cells is the phosphoinositol 
3-kinase (PI3K) pathway (Figure 1.1).  The PI3K pathway is one of the few pathways in 
which mutations have been found in every major element over a broad range of 
cancers.2  PI3K is activated by receptor tyrosine kinases, amplification of which leads to 
overactivation of PI3K and a cancerous cell phenotype.  Many different receptor 
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tyrosine kinases are implicated in cancer through this mechanism: for example, EGFR 
is closely linked to non-small cell lung cancer3 and HER2 to breast cancer.4 PIK3CA, 
the gene which encodes the p110α catalytic subunit of PI3K, is also often mutated or 
amplified in cancer cells, and mutations in the downstream effector Akt and loss of the 
negative regulator of PI3K, PTEN, have both been seen in clinical isolates.  The result 
of any one of these aberrations is upregulation of the PI3K pathway, which leads to a 
cancerous phenotype.2 
 
Figure 1.1 - Signaling the eIF4E-4E-BP PPI and cap-dependent translation. 
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 PI3K inhibitors have been developed in an attempt to modulate this pathway.  
These inhibitors bind in the ATP binding site of PI3K.  Pan inhibitors (such as 
wortmannin) of PI3K are sometimes used in life-threatening diseases in which their side 
effects on the glucose pathway and the immune system can be tolerated short term.  
Isoform specific PI3K inhibitors, some of which have recently been FDA approved5, are 
much more useful in the treatment of cancers in which aberrant PI3K pathways are 
known to exist.  Currently, many isoform specific PI3K inhibitors are in clinical trials.6  
mTORC1 is a key downstream effector in the PI3K pathway 
Activation of PI3K leads to the activation of the downstream kinase complex 
mTORC1.  mTORC1 senses the cell environment to indicate when the cell should grow 
and when growth should be arrested.  The presence of certain amino acids, oxygen, 
and growth factors all activate mTORC1 and induce cell growth, whereas lack of 
energy, hypoxic environments, and stress inhibit mTORC1.  mTORC1 induces 
translation of mRNA through activation of S6K and deactivation of 4EBP1.  Activation of 
mTORC1 also encourages metabolism through induction of nucleotide synthesis 
through the activation of the transcription factor ATF4 and S6K, induces lipid synthesis 
through the activation of transcription factor SREBP, and inhibits autophagy, lysosome 
biogenesis, and proteasome assembly.7   
There are many mTORC1 related processes that are linked to tumorigenesis, 
and mTORC1 functions as a downstream effector of many frequently mutated 
oncogenic pathways.  For instance, mutations in the PI3K/Akt pathway and the MAPK 
pathway both result in mTORC1 hyperactivation in many cancers.7  Dysregulation of the 
mTORC1 pathway has been linked to several human diseases including cancer, 
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obesity, insulin resistance, and autism.8–10  However, the most critical process linked to 
mTORC1’s tumorigenesis is its impact on the eIF4E/4EBP pathway, which regulates 
cap-dependent translation.11–14  This will be further discussed in section 1.4. 
 
1.2 Efforts at targeting mTORC1 
While attempts have been made to target mTORC1 directly using rapamycin, 
rapalogs, and active site inhibitors, these therapies have been mostly unsuccessful due 
to resistance mechanisms observed in many cancers15–23 leading to overactivation of 
the upstream effector Akt,24–27 upregulation of eIF4E,28,29 or downregulation of 4E-
BP.30,31  The rapalogs have also been linked to a negative feedback loop, in which 
inhibition of mTORC1 prevents phosphorylation of S6K, leading to overstimulation of the 
PI3K pathway.  These events result in dysregulation of cap-dependent translation, 
causing an overall increase in the translation of oncogenic mRNAs and a cancerous 
phenotype.32  Two of the rapalogs, everolimus and temsirolimus shown in Figure 1.2, 
have been approved to treat some cancers, including renal cell carcinoma, but for many 
cancers they are ineffective, potentially due to their failure to completely inhibit 
phosphorylation of 4E-BP1.33  Dual mTOR/PI3K inhibitors have been tried to overcome 
the negative feedback loop which ultimately overcomes active-site mTOR inhibitors, but 
concerns have been raised over their toxicity in early clinical trials.  Attempts have also 
been made to link ATP competitive inhibitors with rapalogs in order to better fight mTOR 
resistance mechanisms.33  Resistance to mTOR targeted drugs has been observed 
through mTOR-independent 4E-BP1 phosphorylation,34 incomplete inhibition of 4E-BP1 
phosphorylation,35 downregulation of 4E-BP1 expression,30,31 and amplification of 
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eIF4E.28,29 
 
 
Temsirolimus Everolimus 
Figure 1.2 - FDA approved Rapalogs for targeting certain cancers. 
 
1.3 Cap-dependent translation and its relation to cancer 
Hyperactivation of the PI3K pathway and mTORC1 leads to overactivation of 
cap-dependent translation.  An increase in cap-dependent translation does not cause 
an increase in overall protein expression; rather, it selectively enhances the translation 
of mRNAs encoding for oncoproteins in addition to growth and survival factors.36–39   
 
Figure 1.3 - The 5’ cap of mRNA. 
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mTORC1 modulates cap-dependent translation by controlling the availability of 
eIF4F, which binds to the mRNA 5’ cap, shown in Figure 1.3.40  eIF4F is composed of 
the scaffolding protein eIF4G, the DEAD-box helicase eIF4A, and the rate limiting 
m7GpppX-cap-binding translation initiation factor eIF4E.41    Assembly of the eIF4F 
complex on the 5’ cap of mRNA leads to recruitment of the 40S small ribosomal subunit 
as well as eukaryotic initiation factors 2 and 3.  This process, shown in Figure 1.4, 
begins the assembly of the ribosome and leads to translation of the mRNA. 
 
Figure 1.4 - The cap-dependent translation pre-initiation complex. 
 
eIF4E is elevated in approximately 30% of cancers37,38,40,42–45 and its link to 
cancer has been confirmed through knockdown and knockout studies.46,47,56–58,48–55  
Breast, colorectal, lung, and prostate cancers, glioblastoma, and hematological 
malignancies have all been shown to have increased levels of eIF4E.37,38,40,42–45    Over-
expression of eIF4E has been shown to correlate with poor prognosis and cause 
increased expression of eIF4E-sensitive mRNAs which encode for proliferation and 
survival promoting proteins like the cyclins, cMyc, and Bcl-xl.37,38,40,42–45   
Cellular eIF4E activity is highly regulated through eIF4E expression,59,60 
phosphorylation,61,62 and by the 4E-BPs, which act as gatekeepers of eIF4E by binding 
and sequestering the protein to prevent the formation of the eIF4F translation initiation 
complex and translation.41,63–68  4E-BP activity is regulated by mTORC1 
phosphorylation in which hypophosphorylated 4E-BP binds to eIF4E whereas 
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hyperphosphorylated 4E-BP releases eIF4E to initiate mRNA translation.69–73  
Hyperphosphorylation of 4E-BP is a biomarker for malignancy and patient survival,74–79 
ectopic expression of 4E-BP1 has been shown to suppress tumorigenicity in vitro and in 
vivo,22,80–85 and eIF4E/4E-BP stoichiometry has been shown to directly correlate with 
the sensitivity of cancer cells and tumors to mTOR/PI3K-targeted therapies.32,35,86 
 
Figure 1.5 – Reported ligands on the surface of eIF4E (in blue).  The binding site of 
the 4E-BPs and eIF4G is shown in red, the cap-binding pocket is shown in pink, and the 
allosteric binding site is in green (pictured here is 4EGI-1). 
 
When eIF4E is free from the 4E-BPs, it interacts with eIF4G as part of the eIF4F 
complex.  The eIF4E-eIF4G interaction site is made up of only 15 amino acids and is an 
important target in translational control.41  The 4E-BP suppressors share the binding site 
of eIF4G, and crystal structures indicate that both proteins form a small α-helix upon 
binding.  This binding site, along with the m7GTP binding site and an allosteric binding 
site shown in Figure 1.5, have all been targeted as an attempt to inhibit cap-dependent 
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translation, which will be discussed in the next section. 
1.4 Efforts at targeting cap-dependent translation 
Two small molecules, 4E1Rcat and 4EGI-1, have been identified to purportedly 
target the eIF4E-eIF4G interaction (Figure 1.6).48,87,88  While both compounds show 
anti-proliferative effects, evidence indicates that this is not due solely to their inhibition 
of the eIF4E-4E-BP interaction and cap-dependent translation.48,49,58,89,50–57  4EGI-1 
induces several phenotypes not associated with eIF4E knockdown or knockout48,49,58,50–
57 and its in vitro IC50 of ~25 µM is not consistent with the cellular apoptosis 
data.48,57,58,90,91  This indicates that 4EGI-1’s effects on cancer cell growth are due to 
several off-target effects in addition to inhibition of the eIF4E-4E-BP interaction.  
Additionally, both 4EGI-1 and 4E1Rcat have been shown through X-ray co-crystal 
structures to act through allosteric mechanisms rather than acting as 4E-BP mimetics.92  
From a medicinal chemistry standpoint, neither compound is ideal for drug 
development.  4EGI-1 is known to produce toxic and reactive metabolites and 4E1Rcat 
has been linked to the inhibition of many different systems aside from eIF4E.  
Additionally, both compounds demonstrate flat SAR, have no conclusive target 
identification, and have been identified as pan assay interference compounds 
(PAINS).89,93–95  This evidence indicates that these compounds are not suited for 
validation of the eIF4E-eIF4G PPI as a therapeutic target in human disease.96–98   
m7G-cap analogues have also been explored as eIF4E antagonists (Figure 
1.6),99 but these compounds suffer from poor permeability.100 An exception is the 
analogue 4EI-1, which contains a histidine triad nucleotide binding protein (HINT)-
dependent protecting group, but this compound is only active at concentrations 50 M 
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and shows cell-type-dependent activity.101,102 The antiviral drug, ribavirin, has also been 
reported as an inhibitor of the eIF4Em7G-cap interaction,103 but this has been called 
into question,104 no cellular target identification analyses have been described, and this 
compound has failed to show efficacy in >100 antitumor screens.39 
 
Figure 1.6 – Inhibitors of eIF4E (a.) Known inhibitors of the eIF4E-4E-BP PPI.  
PAINS motifs are shown in red.  (b.) Inhibitors of m7G cap binding. 
 Previously it has been shown that delivery of the 4E-BP1 protein has anti-cancer 
properties in lung cancer mouse models,105 and peptides designed around the 
sequence of 4E-BP are able to bind to eIF4E, inhibit the growth of cancer cells, and in 
some cases induce cell death.106–108  Peptides designed around the eIF4G sequence 
have also been developed, but these compounds are less efficacious than the 4E-BP 
peptides.109  While computational simulations of stapling of an eIF4G peptide showed 
an increase in binding affinity,1 no stapled peptides have been published in relationship 
to this system with any cellular data.  However, the use of helix inducers and mutations 
which encourage alpha helices in the eIF4G peptide have been successful in increasing 
the peptide’s potency.109,110  While initial experiments involving the 4E-BP and eIF4G 
peptides have shown success, they suffer from poor cell permeability and in every case 
require conjugation to cell-penetrating peptides (CPPs), such as penetratin or TAT, or 
conjugation to a hormone to encourage active uptake of the peptides.106–108,110   
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1.5 Research objective 
 The objective of this thesis is to investigate the eIF4E protein-protein interactions 
with 4E-BP and eIF4G and to design inhibitors which are active in vitro and in cellulo.  
Chapter 2 will detail efforts to investigate the binding mechanism of the peptide versions 
of 4E-BP and eIF4G via kinetic studies at varying temperatures and ionic strengths.  
This information will guide the design of stapled peptides based on their binding 
mechanism.  Chapter 3 will describe efforts to improve our first generation stapled 
peptides through mutations to the sequence and staple of the 4E-BP peptides.  Chapter 
4 will outline future investigations into the chemical and metabolic stability of the 
peptides, as well as attempted identification of alternative targets, investigation of 
cellular uptake dependence on staple type, and the synthesis of a functionalized staple. 
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Chapter 2 
An Investigation into the Binding Mechanism of 4E-BP and eIF4G Peptides 
 
2.1 Intrinsically disordered proteins, their role in signaling pathways, and their 
potential as drug targets 
 The most well-known and simplest explanation for the structure of proteins 
originates from Dr. Christian Anfinsen, whose “thermodynamic hypothesis” stated that 
the three-dimensional structure of a protein in its native physiological environment is the 
one in which the system has the lowest Gibbs free energy.  Van der Waals forces, 
hydrophobic and charge-charge interactions, and solvent expulsion all play a part in 
determining which structure is the thermodynamic minimum.  Further implied in 
Anfinsen’s hypothesis is that each amino acid sequence has only one structure, and 
that structure evolved to best perform one biological function.111,112 
 We now know that the relationship between protein sequence, structure, and 
function is not nearly so simple.  NMR and computational studies have shown that 
protein sequences have considerable structural plasticity, and this flexibility has been 
shown to be critical for the protein’s biological function.113  Some proteins interconvert 
between two equally favored thermodynamic minima, others have one primary structure 
but perform multiple seemingly unrelated functions, and still others have no low energy 
state whatsoever, rapidly interconverting between many partially folded states.112,114  
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This last group of proteins, known as intrinsically disordered proteins (IDPs), lack a high 
density of bulky, hydrophobic amino acids, and are therefore unable to form a 
hydrophobic core.  These proteins are key players in numerous crucial cell functions,115 
and prediction algorithms indicate that 33.0% of the eukaryotic proteome either is an 
IDP or contains significant Intrinsically Disordered Regions (IDRs) as opposed to only 
2.0% of archaeon proteins and 4.2% of eubacterial proteins.116   
 The flexibility of IDPs and IDRs allows them to bind a diverse range of 
macromolecules and other proteins to respond to a variety of physiological needs.117–119  
Additionally, they can interact through mechanisms that are disfavored or even 
impossible for globular proteins.120,121  Disorder is commonly seen in proteins that 
regulate the function of multiple binding partners and promote the assembly of multi-
molecular complexes.115,122–125  For instance, hub proteins, which interact with 10 or 
more binding partners, have been shown to be significantly more disordered than end 
proteins, which interact with only one partner, and in general proteins involved in 
regulation, transcription, and development annotations are enriched in disorder.124 
Disordered proteins typically have a “kinetic advantage” over ordered 
alternatives; they are often able to recognize their partner very quickly and exhibit very 
fast on-rates, although this is not always the case.126  This kinetic advantage is 
associated with a process known as “fly-casting,” in which disordered proteins possess 
a larger capture radius which allows them to collide more rapidly with their partner.127  
The specifics of this interaction vary from system to system.  In general, IDPs bind 
through a process known as “coupled folding and binding,” in which the protein folds 
upon binding to its partner.128–130  The order of this process is often described as an 
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“induced fit” mechanism, in which the protein binds through an initial non-specific 
interaction and then folds to the final bound state, or a “conformational selection” 
mechanism, in which the protein folds into the preferred conformation and then binds in 
a single event.131  However, it is likely that IDP mechanisms of interaction are much 
more complex.  The “dock and coalesce” mechanism, in which the initial interaction 
catalyzes the binding of the remaining segments,132 formation of “fuzzy complexes,” in 
which the IDP remains disordered even after binding,133 and multistep mechanisms with 
multiple parallel pathways134 have all been used to describe interactions made by 
various IDPs. Additionally, it is important to remember that these mechanisms are 
observed in vitro, and the true method of association likely varies based on 
environmental conditions, competition, compartmentalization, and reactant 
concentrations. 
Determining the binding mechanism of disordered interactions is quite 
challenging due to the complexity of the many weak, non-covalent interactions, but 
structural, kinetic, and dynamics data can be used to figure out some details.131  
Observing the helicity of the IDP can provide information about binding properties, but 
does not necessarily inform about the mechanism, since a correlation between helicity 
and association constant could be explained as an increased rate of binding of the 
folded helix or a stabilization of the transition state for folding after binding.135–137 
However, one can observe binding kinetics under pseudo-first order experiments with 
respect to each ligand to differentiate between induced fit and conformational 
selection.138  Comparing rate constants at different temperatures and solvent conditions 
can also provide information about the binding mechanism.139  While in many cases the 
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mechanism cannot be definitively proven with these methods, they can be used to 
understand more about the protein interactions and how to perturb them. 
Given the prevalence of disordered proteins in key cellular processes, as well as 
their ability to participate in a wide variety of interactions, it should come as no surprise 
that disordered proteins have been associated with cancer140,141 and neurodegenerative 
disorders and are now being investigated as potential drug targets.142,143  However, 
disordered proteins are challenging drug targets due to their lack of tertiary structure, 
the dynamic or transient nature of what structure they do have, and the many potential 
mechanisms of binding.  Early efforts to target IDPs include the use of small molecules 
to bind partially folded regions of the protein,144,145 the inhibition of PPIs between 
disordered and ordered proteins in which the inhibitor binds to the ordered partner (for 
instance, nutlins, which inhibit the p53-MDM2 PPI),146 and the use of compounds to 
induce structure formation, leading to loss of function of the IDP.147  Computational 
methods have also been helpful in trying to target IDPs, although more work is 
necessary to optimize computational tools for disorder-based drug design.148 
 The focus of this thesis is primarily to inhibit the eIF4E-eIF4G protein-protein 
interaction.  However, eIF4G and the 4E-BPs, which both bind in the same site on the 
surface of eIF4E, are disordered proteins.  In fact, nearly 75% of the residues in eIF4G 
are classified as disordered, and eIF4G is predicted to have 18 disordered binding 
sites.149  The 4E-BPs are completely unstructured in solution, but their eIF4E binding 
site has been shown to have high helical propensity.  Interestingly, the 4E-BP2 protein 
still maintains some disorder after complexing with eIF4E, forming a somewhat “fuzzy” 
complex.150,151  Phosphorylation by mTORC1 or other kinases decreases the helical 
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propensity at the binding site, which causes the 4E-BPs to favor an unfolded (or 
incorrectly folded) state which cannot bind to eIF4E.152,153 
 In order to inhibit this interaction, it was important to consider other methods for 
inhibiting intrinsically disordered interactions.  In the work to be presented, the probe will 
be binding to eIF4E, which is a mostly ordered protein; however, the peptide binding 
surface of eIF4E is quite planar, lacking any distinctive feature to recognize eIF4G or 
4E-BP1.1  A small molecule approach (which has been tried before, and is described in 
Chapter 1) seemed unlikely to succeed.  Since the eIF4E interacting residues of eIF4G 
and 4E-BP1 are structural mimics of each other, forming a short helix once bound,67 
we decided to attempt to mimic the disordered proteins which bind to eIF4E’s surface.  
Thus, the goal of this chapter was to use, to the best of our ability, the methods 
described in the literature to compare the binding mechanisms of eIF4G and 4E-BP1 
peptides to eIF4E, and to use that information to discern the best way to target this 
pathway through the use of 4E-BP1 and eIF4G peptides.   
 While there is some information available concerning the binding mechanism of 
the full-length 4E-BP proteins, there is less information regarding the 4E-BP or eIF4G 
peptides.  The full-length 4E-BP and eIF4G proteins interact via a bipartite mode, which 
involves the canonical binding sequence as well as a second binding site shown in 
Figure 2.1.150,154  The binding of 4E-BP1 peptides, which contain only the canonical 
binding site, is 23 fold weaker than that of the full-length 4E-BP1 protein.155,156  
Additionally, it has been suggested that 4E-BP1 must first bind in the second, non-
canonical binding site in order to displace eIF4G and repress translation.157   
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Figure 2.1 – Overlay of 4E-BP1 
(red/purple) and eIF4G (blue/teal) 
bound to eIF4E.  The residues of the 
canonical binding site are shown.  The 
secondary binding site is shown it 
purple for 4E-BP1 and teal for eIF4G.  
PDB ID 4UED and 5T46. 
 Figure 2.2 – Bound structure of 
the linear 4E-BP1 (red) and 
eIF4G (blue) peptides that we 
intend to use for our studies. 
We were interested in developing mimics of the eIF4G or 4E-BP proteins in order 
to better probe the system, validate eIF4E as a target, and ultimately aid in the 
development of a cancer therapeutic.  It therefore made sense to use only the canonical 
binding site (plus some flanking amino acids) for our studies, which consists of 16 
amino acids for 4E-BP1 and 14 amino acids for eIF4G (Figure 2.2).  We were unsure of 
the effect of truncation on the binding mechanism of these short peptides and what that 
would mean for our attempts to use them as inhibitors of the eIF4EeIF4G protein-
protein interaction.  Additionally, while constraining peptides through stapling or 
cyclization has been used in the past (and will be discussed in Chapter 3) to improve 
their drug-like properties, we did not know how this technique would apply to disordered 
peptides.  The aim of this chapter was to explore the binding mechanism of the 4E-BP1 
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and eIF4G peptides and to apply that information to the development of a probe for cap-
dependent translation, but along the way, we also learned about larger implications 
involving mimicking IDPs.   
2.2 Helical propensity and inhibitory potential of 4E-BP1 and eIF4G peptides 
 We compared several peptides based around the sequences for 4E-BP1 and 
eIF4G (Table 2.1).  Our longest peptide, 4E-BP1 (G49N64), was chosen based on the 
crystal structure of a peptide containing the canonical binding sequence bound to 
eIF4E.  The eIF4G peptide also encompasses the canonical binding site (eIF4G 
K608F622), although it is slightly shorter (only 14 amino acids as opposed to 16) 
because we wanted both peptides to have the same total charge, and extending the 
eIF4G peptide to include all 16 residues would add two additional glutamate 
residues.67  We therefore also tested a slightly truncated 4E-BP1 peptide, 4E-BP1 
(R51N64), in order to confirm that the differences we observed were not only due to 
sequence length.  We also examined a linear version of sTIP-04, which is a stapled 
eIF4G peptide previously described in the literature, eIF4G (K608-F620, D613S, F616Q, 
F620L).1 sTIP-04 will be discussed in more detail in Chapter 3.  Finally, we tested a 
4EBP1/eIF4G hybrid peptide, 4E-BP1 (R51N64, R51K, I52K, I53R). 
We found that the 4E-BP1 peptides had much better IC50s (curves for all 
peptides are in Chapter 2 – Supplemental Information - IC50s) than their eIF4G 
analogues.  Interestingly, the 4E-BP1/eIF4G hybrid peptide significantly lost activity 
(10-fold reduction over the native 4E-BP1 sequence) with the introduction of the KKR 
on the N-terminus.  This hybrid peptide was actually 3-fold worse than the eIF4G 
peptide, indicating that the addition was definitely not beneficial to activity.  Also, the 
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linear version of sTIP-04 had a worse IC50 than the un-mutated eIF4G sequence, 
which was surprising because that sequence was optimized by Phage display, and its 
stapled version has a very high affinity for eIF4E (this will be discussed later in this 
chapter). 
Table 2.1 – Sequences, IC50s, and helicities of linear peptides.  IC50s were measured 
using cat-ELCCA and curves are shown in Supplemental Information 2.1. 
  
     Y X X X X L φ     
 
IC50 (nM) %Helicity 
% Helicity 
(40% TFE)   
         
 
4E-BP1 (G
49N64) G T R I I Y D R K F L M E C R N 
 
70 ± 20  16 37 
 
4E-BP1 (R
51N64)   R I I Y D R K F L M E C R N 
 
41 ± 9 14 46 
 
4E-BP1 (R
51N64), 
R
51
K, I
52
K, I
53
R   
K K R Y D R K F L M E C R N 
 
420 ± 98 8 28  
eIF4G (K
602F622)   K K R Y D R E F L L G F Q F 
 
160 ± 30 3 24 
 
eIF4G (K
602F620), 
D
613
S, F
616
Q, F
620
L   
K K R Y S R E Q L L G L 
  
 
500 ± 100 4 13 
  
The 4E-BP1 peptides were also more helical than the eIF4G peptides, although 
all of the peptides were still mostly unstructured (Figure 2.3).  We also tested helicity 
in the presence of trifluoroethanol (TFE), which induces helicity, in order to observe 
the propensity for helicity.  We found that the 4E-BP1 peptides had a greater helical 
propensity, the hybrid peptide averaged the helicities of the 4E-BP1 and eIF4G 
peptides, and the linear version of sTIP-04 had the least potential for helicity.  Curves 
for all peptides are in Chapter 2 – Supplemental Information – CD. 
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 Phosphate Buffer 
Phosphate Buffer 
+ 40% TFE 
4E-BP1 (G
49N64) 16% 37% 
4E-BP1 (R
51N64) 12% 41% 
4E-BP1 (R
51N64) R51K, I52-K, I53R 8% 28% 
eIF4G (K
608F622) 3% 24% 
eIF4G (K
608F620) D613S, F616Q, F620L 4% 13% 
Figure 2.3 – Percent helicity of the linear 4E-BP1 and eIF4G peptides in buffer 
(top) and with the helicity inducer, trifluoroethanol (bottom). 
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2.3 Kinetic analysis of 4E-BP1 and eIF4G peptides 
Table 2.2 – Kinetic binding data for linear peptides determined by SPR. 
 Ka (M
-1
s
-1
) Kd (s
-1
) KD (nM) 
4E-BP1 (G
49N64) 0.82 ± 0.3 x 10
6
 2.1 ± 0.4 x 10
-2
 26 ± 6 
4E-BP1 (R
51N64) 1.10 ± 0.01 x 10
6 
1.92 ± 0.03 x 10
-2
 17.5 ± 0.3 
4E-BP1 (R
51N64), R51K, I52K, I53R 2.0 ± 0.9 x 10
6
 15 ± 2 x 10
-2
 77 ± 7 
eIF4G (K
602F622) 1.7 ± 0.3 x 10
6 
4.8 ± 0.9 x 10
-2
 29 ± 6 
eIF4G (K
602F620), D613S, F616Q, F620L 1.99 ± 0.06 x 10
6
 12.3 ± 0.8 x 10
-2
 62 ± 4 
 
 In order to further elucidate the mechanism, we measured the ka, kd, and KD 
values for each linear peptide at room temperature using Surface Plasmon Resonance 
(SPR) spectroscopy (Table 2.2).  We found that the eIF4G peptides exhibited much 
faster kas than the 4E-BP peptides.  We hypothesized that this could be due to the 
KKR sequence on the N-terminus of the eIF4G peptides, which is known to contribute 
to the “fly-casting” ability of many intrinsically disordered proteins.  Indeed, the 4E-BP1 
peptide with the mutated KKR N-terminus also has a faster (almost 2-fold) association 
rate than the un-mutated 4E-BP1 peptides.  The hybrid 4E-BP1/eIF4G peptide had the 
worst dissociation rate of all, which likely explains its significantly worse IC50.  The 4E-
BP1 peptides had slower off-rates than the eIF4G peptides, and generally had 
stronger binding constants.  While we suspected that these differences could be 
explained by a difference in binding mechanism of the two peptide sequences, more 
experiments were required to support our hypothesis.  Sensorgrams for all peptides 
are in Chapter 2 – Supplemental Information – SPR. 
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Figure 2.4 – The kinetics of binding of the 4E-BP1 and eIF4G peptides in 
response to increasing temperature as determined by SPR. The full length 
peptides 4E-BP1 (red) and eIF4G (blue) peptides are on the left series of graphs, and 
the truncated 4E-BP1 (red) and mutated eIF4G (blue) peptides are on the right series 
of graphs.  The y-axis from top to bottom is the ka, kd, and KD. 
As discussed in section 4.1, IDPs and IDRs have been shown to be affected by 
temperature, so we next analyzed the binding kinetics of the peptides between 10°C 
and 30°C (Figure 2.4).  4E-BP1 (G49N64) had an increased on-rate and off-rate with 
increasing temperature, but ultimately only a very small increase in the binding 
constant.  The truncated 4E-BP1 (R51N64) peptide had an on-rate unaffected by 
temperature, an increase in off-rate, and an increase in the binding constant.  This 
was surprising, because we expected these two very similar peptides to behave the 
same.  Since the truncated 4E-BP1 peptide is slightly less ordered than the full-length 
peptide, it is possible that some preordering of this sequence is required for the initial 
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interaction. eIF4G (K608F622) had an unchanged on-rate and a significant increase in 
off-rate with increasing temperature, leading to a significantly higher binding constant.  
This looks more similar to the behavior of the shorter 4E-BP1 peptide, and the 
decreased helicity of the eIF4G peptide correlates with its much weaker binding 
overall.  The mutated linear peptide based off the sequence of sTIP-04 followed the 
same trends as eIF4G, but, as expected, the overall binding of this peptide was 
weaker. 
  
  
  
Figure 2.5 – The kinetics of binding of 4E-BP1 and eIF4G peptides in response 
to increasing ionic strength.  The left series of graphs compares the full length, 
unmutated 4E-BP1 (red) and eIF4G (blue) peptides.  The right series compares the 
truncated 4E-BP1 (red) and mutated eIF4G (blue).  From top to bottom, the y-axis is 
ka, kd, and KD.  Note that eIF4G (K
608F620), D613S, F616Q, F620L has two sets of kinetic 
data at 1000 mM NaCl from its two binding events. 
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 To further probe the binding mechanism of the peptides, we measured the 
binding kinetics at 225 mM, 500 mM, and 1000 mM sodium chloride (Figure 2.5).  We 
found that the 4E-BP1 (G49N64) peptide had a slightly increased on-rate, an 
unchanged off-rate, and an improved binding constant in response to increasing salt 
concentrations.  This trend was reversed in the case of the shorter 4E-BP1 peptide, in 
which the off-rate and binding constant increased with ionic strength.  eIF4G 
(K608F622) had a larger increase in on-rate, a corresponding increase in off-rate, and 
an overall weaker binding constant in response to increasing salt concentrations.  The 
mutated eIF4G peptide had a much slower on-rate and off-rate at high ionic strength.  
This is surprising, as it appears to behave more similarly to the 4E-BP1 peptide, 
although the decrease in on-rate is unique.  This indicates that the mutated eIF4G 
peptide has changed its mechanism of interaction in some way with increasing ionic 
strength.   
We next considered if the observed differences were due to changes in peptide 
or eIF4E stability across temperatures or salt concentrations (Figure 2.6).  The 
peptides appeared to have the same conformation over all temperatures tested.  A 
slight change in conformation was observed at 1 M sodium chloride versus 0 M.  
Sodium chloride distorts the spectrum significantly below 200 nm, which is why we 
only reported wavelengths between 200260 nm.  The differences in the spectra are 
only observed at less than 210 nm, so it is possible that the salt itself, rather than a 
change in conformation, is responsible for the low UV shift.  However, it is also 
possible that the peptides in 1 M sodium chloride have less “random coil” character 
than those without salt.  In any case, the salt does not appear to affect the helicity of 
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the peptides (seen around 222 nm).  We also found that eIF4E was stable at the 
temperatures tested in SPR for at least 20 min, which is the length of the assay 
(Figure 2.7). 
  
  
  
Figure 2.6 – The effect of temperature (top four images) and salt (bottom two 
images) on the conformation of the peptides. 
 
Based on this data, we hypothesize that the eIF4G peptide binds through an 
induced fit mechanism.  Its fast on-rate and the KKR sequence on the N-terminus are 
consistent with a peptide binding through the fly casting mechanism.  Additionally, it 
appears to form a less stable complex with eIF4E (as opposed to the 4E-BP1 peptide).  
This is evidence by its increased off-rate in the presence of increased temperature and 
higher ionic strength.  We propose that eIF4G forms a very quick initial interaction, but 
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is much slower to fold into its final helical form.  4E-BP1, on the other hand, has both a 
slower on-rate and off-rate compared to the eIF4G peptide.  Additionally, its binding 
constant is unaffected by increasing temperature and actually improved by increasing 
ionic strength.  We hypothesize that the 4E-BP1 peptide binds via a conformational 
selection mechanism, in which it first forms a helix in solution and then binds to eIF4E.  
This could explain the greater stability of the eIF4E4E-BP1 complex, because the 
peptide has already folded into the appropriate helix upon binding.  However, it appears 
that the mechanism of interaction is highly sequence dependent, because we observe 
differences in kinetics with only a short truncation in the case of 4E-BP1 and a few 
mutations (and additional truncation) in the case of eIF4G. 
 
Figure 2.7 – eIF4E CD spectra across temperatures tested in SPR.  We also 
observed the spectra at 60 and 80 degrees to indicate the expected change in 
spectra with denaturation. 
  
2.4 Consideration of binding mechanism in designing IDP mimetics 
 In order to see how our observation of peptide kinetics would affect our efforts 
to make a constrained peptide probe, we made a series of stapled peptides and 
compared their activity versus eIF4E.  Dr. James Song synthesized a hydrocarbon 
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stapled 4E-BP1 (G49N64), hereafter referred to as HCS 4E-BP1.  Dr. Song also made 
the sTIP-04 peptide from the literature, and a hydrocarbon stapled 4E-BP1 negative 
control, HCS-4E-BP1 (G49N64), L59A, M60A, hereafter referred to as HCS 4E-BP1 LM-
>AA.  Alyah Chmiel made a hydrocarbon stapled eIF4G (K608F620), referred to as 
HCS eIF4G.  The sequences and IC50s of these peptides are shown in Table 2.3. 
Table 2.3 – Sequences, IC50s, and helicities of 4E-BP1 and eIF4G stapled peptides.  
X = pentenyl alanine. 
  
     Y X X X X L φ     
 
IC50 (nM) %Helicity 
% Helicity 
(40% TFE)   
         
 
HCS 4E-BP1 G T R I I Y D R X F L M X C R N 
 
5 ± 2  44 83 
 
HCS 4E-BP1  
LM->AA 
G T R I I Y D R X F A A X C R N 
 
8000 ± 7000 35 64 
 
HCS eIF4G 
  
K K R Y D R X F L L X F 
  
 
6000 ± 1000 5 19 
 
sTIP-04 
  
K K R Y S R X Q L L X L 
  
 
24 ± 7 38 58 
 
 The stapled 4E-BP1 peptide showed a significant improvement in IC50, as one 
might expect based on stapled peptide literature.  However, HCS eIF4G actually 
showed a significant loss of potency; the linear eIF4G peptide had an IC50 of 29 nM, 
but upon stapling the IC50 increased to 6 µM.  Interestingly, sTIP-04, which has been 
mutated to favor a helical conformation, has an IC50 of 24 nM.  The IC50s of the 
stapled peptides correlate reasonably well with helicity (Figure 2.8), in which the two 
best peptides, HCS 4E-BP1 and sTIP-04, are quite helical, whereas HCS eIF4G is not 
helical at all.  A notable exception is HCS 4E-BP1 LM->AA, which is 35% helical but 
lacks activity.  Interestingly, even the addition of TFE to HCS eIF4G does not cause it 
to form an alpha helix.  The curve lacks distinct dips at 222 and 208 nm, which can be 
clearly seen in the spectra for the other three peptides.  This indicates that HCS eIF4G 
not only lacks intrinsic helicity, but also lacks the propensity for helicity. 
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Figure 2.8 – Circular dichroism spectra for the stapled peptides in phosphate 
buffer (left) and with the addition of 40% TFE (right). 
 
 We next tested the stapled peptides for kinetic binding (Table 2.4).  We did not 
test HCS 4E-BP1 LM->AA due to its weak activity which would be difficult to observe 
by SPR.  The HCS 4E-BP1 peptide had an improved on-rate and off-rate over its 
linear counterpart, leading to an improved binding constant of 4 nM.  HCS eIF4G also 
had an improved off-rate, but its on-rate was significantly slower than the linear eIF4G 
peptide, which is what lead to its overall loss in affinity.  This could be explained by its 
decreased propensity for helicity.  Interestingly, the sTIP-04 peptide also had a slower 
on-rate relative to the linear peptide, but its off-rate was improved enough to lead to a 
stronger binding peptide.  Constraining the peptides improved the dissociation 
constant in all cases, but only improved the association constant for the 4E-BP1 
sequence.  This appears to support our hypothesis that the 4E-BP1 sequences binds 
through a conformational selection type mechanism, whereas the eIF4G sequence 
binds through induced fit.  Constraining (or ordering) the eIF4G peptides reduces the 
association rate, likely because they now lack the kinetic advantage lent by their 
disorder.  The 4E-BP1 sequence, however, seems to require a helical conformation to 
bind in the first place, so stapling lowers the barrier for that first step.   
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Table 2.4 – Kinetic binding data for stapled peptides determined by SPR. 
 
 
Ka (M
-1
s
-1
) Kd (s
-1
) KD (nM) 
HCS 4E-BP1 
 
1.5 ± 0.2 x 10
6
 5 ± 4 x 10
-3
 4 ± 3 
HCS eIF4G 
 
0.33 ± 0.01 x 10
6
 30 ± 4 x 10
-3
 90.0 ± 0.3 
sTIP-04 
 
0.83 ± 0.05 x 10
6 
5.2 ± 0.1 x 10
-3
 6.3 ± 0.4 
 
2.5 Cell penetration and activity of HCS peptides 
 To confirm that the peptides entered the cell, we used FITC labeled stapled 
peptides and observed cell penetration using confocal imaging.  These imaging 
studies were performed by Arya Menon, and the results are shown in Figure 2.9.  All 
three of the peptides entered the cell.  Videos of the cells (not shown) indicate that the 
fluorescent blobs are inside the cell and not stuck to the surface.  Surprisingly, the 
peptides are clustered in blobs inside the cell.  It is possible that the peptides 
aggregated once inside the cells, that they are localizing to stress granules,158 or that 
they have localized to different cellular compartment.  The physical properties of the 
peptide are altered with the introduction of the FITC tag, so it is unclear if the 
untagged peptide would behave the same.  Going forward, we use a different type of 
cell penetration assay, which will be described in Chapter 3. 
To determine if the peptides were effective in cancer cells, we used an eIF4E 
pulldown assay which was performed by Arya Menon.  The cells were treated with 
peptide for 6 hours and then lysed.  M7GDP immobilized on resin was added to the 
cell lysate in order to bind eIF4E.  The resin was washed, boiled, and the proteins 
were run on a gel to be analyzed by Western Blot.  We used eIF4E as a normalization 
control, and looked for a decrease in pulldown of eIF4G and 4E-BP1 proteins in the 
presence of peptide.  The results are shown in Figure 2.10. 
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Figure 2.9 – Confocal imaging of FITC labeled peptides inside the cell. 
  
A B 
 
C 
 
Figure 2.10 – eIF4E pulldown data for 4E-BP1 (G49N64) and HCS 4E-BP1 in (A) 
MDA-MB-231 cells, (B) HCT116 cells, and (C) H1299 cells (both HCT116 and H1299 
were treated with 2.5 µM peptide). 
 
 We found that HCS 4E-BP1 partially inhibited the pulldown of both eIF4G and 
4E-BP1 in all cell lines.  The linear 4E-BP1 peptide was not active at 2.5 µM and was 
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less active at 5 µM when compared with the stapled peptide.  We see activity in the 
pulldown assay against MDA-MB-231 cells (a triple negative breast cancer cell line), 
HCT116 cells (a colon cancer cell line), and H1299 cells (a non-small cell lung 
carcinoma cell line). 
 
2.6 Conclusion 
It is impossible to definitively prove the mechanism of interaction of the 4E-BP1 
and eIF4G peptides, but our data shown here does indicate that they interact with eIF4E 
differently.  Based on this evidence, we believe that 4E-BP1 goes through a 
conformational selection mechanism, whereas eIF4G binds through an induced fit 
mechanism, although we acknowledge that the actual method of interaction could be 
more complicated.  In order to further dissect the peptideprotein interactions, the next 
logical study would be a stopped flow experiment in which one could measure the 
kinetics of interaction under pseudo first order conditions. 
Interestingly, the mutant eIF4G peptide (eIF4G K608F620, D613S, F616Q, F620L) 
seems to also go through an induced fit mechanism and has very similar properties 
compared to eIF4G (K608F622).  However, the stapled version of this mutant, sTIP-04 is 
significantly more helical than HCS eIF4G.  This indicates that the mutations within this 
peptide do not promote ordering of the linear peptide, but allow the stapled peptide to 
achieve a stable and helical structure.  This indicates that the secondary structure of a 
linear disordered peptide does not predict helical stabilization through stapling.  We 
hypothesize that the linear eIF4G peptide is only capable of binding through an induced 
fit mechanism, but the mutations introduced by Lama et. al.1 enable the sequence to 
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bind through either an induced fit or a conformational selection mechanism.  This would 
indicate that only peptides which can bind through either mechanism are suitable for 
helical constraint.  For peptides which cannot bind through a conformational selection 
mechanism, mutations to alter the folding landscape (as with sTIP-04) or receptor-
templated stapling are potential alternatives for the design of constrained peptides.159 
 
2.7 Materials and Methods 
Development of the SPR Assay 
pET19b-PP-eIF4E 
A pET19B vector containing a His10 tag and a precission protease cut site was gifted 
to me by Dr. Max Stefan in Dr. George Garcia’s lab.  The human eIF4E gene was 
amplified using PCR with the following primers: 
Forward Primer 5’ GGTACATATGGCGACTGTCGAACCGGA 3’ 
Reverse Primer 5’ CATCGGATCCTTAAACAACAAACCTAT 3’ 
 
   
The PCR reaction components were: 
Component Concentration Volume 
PFU Ultra Buffer 10X 5.0 µL 
dNTPs 25 mM (each base) 0.5 µL 
eIF4E Template 450 ng/µL 0.5 µL 
Forward Primer 100 ng/µL 2.0 µL 
Reverse Primer 100 ng/µL 2.0 µL 
PFU Ultra 2.5 U/µL 1.0 µL 
Water  39 µL 
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The PCR reaction conditions were: 
Initialization 95°C 2 min   
     
Denaturation 95°C 30 s   
Annealing 56°C 30 s 35 Cycles 
Elongation 72°C 1 min  
     
Final Elongation 72°C 10 min   
 
The amplified eIF4E was purified with a Qiagen PCR Purification Kit.  The pET19B 
vector and the amplified eIF4E were digested (in separate vessels) with NdeI and 
BamHI at 37°C for 1 hour.  The reaction components were: 
 
Component Concentration Volume 
eIF4E 43.5 ng/µL 23.5 µL 
OR   
pET19B PP 30 ng/µL 33.0 µL 
Buffer B 10X 5.0 µL 
NdeI 10 U/µL 1.0 µL 
BamHI 10 U/µL 1.0 µL 
Water  19.5 µL (eIF4E); 10 µL (pET19B PP) 
 
The digested pET19B PP vector was further treated with calf-intestinal phosphatase 
for 30 minutes at 37°C and then purified with a Qiagen Gel Purification Kit.  The eIF4E 
PCR digest was purified using a Qiagen PCR Purification Kit. 
The purified pET19B PP vector and eIF4E insert were ligated over night at 16°C using 
the following reaction components: 
Component Concentration Volume 
eIF4E insert 14 ng/µL 1.14 µL 
pET19B PP vector 7 ng/µL 7.0 µL 
Ligase Buffer 10X 2.0 µL 
DNA Ligase 6 U/µL 1.0 µL 
Water  8.9 µL 
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DH5α cells were transformed using 4 µL of the ligation mixture.  The competent cells 
were thawed on ice and incubated with the ligation mixture for 20 minutes.  The cells 
were then heat-shocked at 42°C for 30 seconds, and then returned to ice for 2 
minutes.  350 µL of LB-media were added to the cells, and the mixture was shaken at 
225 rpm at 37°C for 1 hour.  20 µL of this mixture was plated onto an LB agar plate 
spiked with 50 µg/mL ampicillin.  Colonies were picked and sequenced to determine if 
the cloning was successful.  The final plasmid was isolated via a Qiagen Mini Prep Kit 
and used to transform BL(21)-DE3 cells with the same method described above. 
 
m7GTP Cap-Affinity Resin 
The cap-affinity resin was synthesized as previously described.160  0.5 mL of 10 mM 
m7GTP, 0.1 mL of Sodium Acetate Buffer pH 6, and 5 µmoles of Sodium Periodate 
were mixed in a glass vial wrapped in foil.  The vial was incubated at 4°C for 1.5 hours 
without shaking.  1 mL of packed adipic dihydrazide resin was washed with 20 mL of 
water followed by 20 mL of the Sodium Acetate Buffer.  The m7GTP mixture was 
transferred to the resin along with 2 mL of the Sodium Acetate Buffer.  This mixture 
was turned end over end at 4°C for 1.5 hours.  5 mg of Sodium Cyanoborohydride was 
added to the mixture, and it was turned end over end overnight at 4°C.  The resin was 
washed at least 5 times with 10 mL of 1 M Sodium Chloride.  It was then rinsed with 
Phosphate Buffer pH 7, suspended in about 2 mL of the Phosphate Buffer, and stored 
at 4°C. 
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His10 eIF4E Expression and Purification 
1 L of LB media was spiked with 50 µg/mL ampicillin and inoculated with 10 mL of 
starter culture.  The culture was grown until the OD600 = 0.8, at which point it was 
cooled to 16°C, induced with 1 mM IPTG, and shaken over night at 180 rpm.  The next 
morning, the cells were pelleted at 3095xg for 20 minutes.  The pellets were frozen 
between protein expression and purification. 
The cell pellets were thawed and resuspended in Lysis Buffer (50 mM Sodium 
Phosphate pH 7.4, 100 mM Sodium Chloride, 0.5 mM PMSF, 0.5 mM EDTA, 5 mM β-
mercaptoethanol, 0.5% Tween 20, 1 mM DTT).  The suspension was sonicated at 
60% with 5 second pulses followed by 15 seconds of rest for a total of 2 minutes of 
sonication.  The lysate was clarified by centrifugation at 38,000xg for 2 hours.  The 
clarified lysate was incubated with m7GTP cap-affinity resin for 45 minutes and the 
protein bound resin was collected via gravity filtration.  The resin was washed with 8 
mL of Lysis Buffer followed by two 8 mL washes with Wash Buffer (50 mM Sodium 
Phosphate pH 7.4, 100 mM Sodium Chloride).  The resin was incubated with 5 mL 
Elution Buffer (50 mM Sodium Phosphate pH 7.4, 100 mM Sodium Chloride, 100 µM 
m7GTP, 5% Glycerol) for 15 minutes, after which the eluate was collected by filtering 
off the resin.  The eluted protein was typically about 0.5 mg/mL for a total yield of 2.5 
mg.  The protein was stored without concentrating in 50 µL aliquots at -80°C.  A 
representative protein gel is shown in Figure 2.11.  A large amount of the protein was 
not soluble, however enough was isolated from the soluble fraction for the SPR assay. 
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Figure 2.11 – Typical coomassie gel of His10 eIF4E purification. 
 
Optimization of the SPR Assay 
SPR assays were performed on a SensiQ Pioneer instrument using His Cap chips.  
The chip was conditioned with the following sequence of injections over all three 
channels: 
Component Injection Volume Flow Rate 
10 mM HCl 20 µL 10 µL/min 
50 mM NaOH 20 µL 10 µL/min 
0.1% SDS 20 µL 10 µL/min 
10 mM HCl 20 µL 10 µL/min 
50 mM NaOH 20 µL 10 µL/min 
0.1% SDS 20 µL 10 µL/min 
500 mM EDTA, pH 8 100 µL 20 µL/min 
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Due to the instability of eIF4E and the slow off-rates of our peptides, the chip was 
completely regenerated for each analyte injection.  The following indicates the typical 
injection sequence for each cycle: 
Component Injection Volume Flow Rate Post Time 
500 mM EDTA, pH 8 100 µL 20 µL/min 100 s 
50 µM NiCl2 20 µL 10 µL/min 30 s 
18 µg/mL His10 eIF4E 100 µL 10 µL/min 30 s 
0.5 mg/mL BSA 10 µL 10 µL/min  
Analyte 50 µL 50 µL/min 120 s 
10 mM HCl 5 µL 10 µL/min  
50 mM NaOH 5 µL 10 µL/min  
0.1% SDS 5 µL 10 µL/min  
 
The His10 eIF4E and BSA were diluted using SPR Running Buffer (10 mM Hepes pH 
7.5, 225 mM Sodium Chloride, 10 mM Imidazole, 0.1% Tween 20, 5% Glycerol).  The 
analyte was lyophilized from water and then dissolved in the SPR Running Buffer.  
Peptides were typically tested at 5 concentrations between 25 nM and 1 µM. 
Curves were analyzed with QDAT software using a 1:1 ratio to determine on-rates, off-
rates, and binding constants.   
For kinetic analysis, peptide binding kinetics were analyzed at 10, 15, 20, 25, and 
30°C, and at 225, 500, and 1000 mM Sodium Chloride. 
Cat-ELCCA 
IC50’s were calculated using a catalytic Enzyme Linked Click Chemistry Assay (cat-
ELCCA), which was developed by my colleague and co-author Dr. James Song.  In 
brief, biotinylated eIF4E was immobilized in a streptavidin coated 384 well plate.  The 
peptide (at 18 different concentrations in duplicate) was added to the well first, 
followed by 4E-BP1 protein with an m-tetrazine tag.  This mixture was allowed to 
incubate for 1 hour, at which point the wells were washed thoroughly prior to 
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incubation with HRP tagged with trans-cyclooctene for one hour.  After the click 
reaction, the wells were washed and then incubated with HRP substrate.  
Chemiluminescence was read with a plate reader.  Except where noted otherwise, this 
assay was performed in triplicate (on three separate days) to obtain final IC50 curves.  
Data was analyzed using a nonlinear regression dose response analysis with variable 
slope in Graphpad Prism.   
Peptide Synthesis 
Linear peptides were purchased from New England Peptide.  Stapled peptides were 
synthesized by Dr. James Song, except for HCS-eIF4G, which was synthesized by 
Alyah Chmiel.  The peptides were synthesized and purified using methods similar to 
those described in Chapter 3. 
Circular Dichroism 
Peptides were dissolved to 100 µM in 5 mM sodium phosphate buffer, pH 7.4.  Data 
was recorded using a Jasco I-1500 CD-Spectropolarimeter.  Measurements were 
taken between 180 and 260 nm with a step resolution of 0.1nm and a speed of 100 
nm/sec.  For the CD spectra of eIF4E, measurements were taken between 200 and 
300 nm, and for the peptides dissolved in 1M NaCl, measurements were taken 
between 200 and 260 nm.  5 accumulations were taken with the response time set to 
1 s, bandwidth to 5 nm, and pathlength of 0.1 cm. The α-helical content of each 
peptide was calculated by dividing the mean residue ellipticity [φ]222obs by the 
theoretical [φ]222 for a helical acetylated peptide of equivalent length.  For 
determination of temperature dependence, 100 µM samples were equilibrated to 10 
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°C, 15 °C, 20 °C, 25 °C and 30°C, and measurements were taken as above at each 
temperature. 
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Chapter 3 
Designing a Stapled Peptide to Probe the eIF4E–eIF4G PPI 
 
3.1 Stapled peptides 
 Peptides have several advantages over small molecule inhibitors when 
considering protein–protein interactions.  While small molecules typically require some 
kind of pocket to bind with any specificity, peptides have been designed by nature to 
specifically bind to large, flat protein surfaces.  However, peptides often require cell 
penetrating sequences in order to access targets in the cytoplasm or nucleus, which 
can increase the cost and the potential for toxicity, and once inside the cell they are 
subject to cleavage by proteases.  Stapling, or covalently linking two amino acid side 
chains to stabilize the α–helix, has been proposed as a solution to some of these 
problems, since increased helicity reduces the exposure of the amide backbone, 
which can potentially shield from proteases and increase cell penetration. 
 Early efforts to constrain peptides into a helix involved the use of hydrophobic 
residues, salt bridges, and the introduction of different helix capping groups to non-
covalently stabilize the helix.161–166  Stabilization with lactam staples167 and disulfide 
bridges168 have also been explored to covalently increase helicity.  In 1998, the 
Grubbs group published the first use of olefin metathesis for peptide stapling, in which 
they used allyl serine derivatives for the metathesis and observed a small increase in 
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helicity.169  This work was followed by the Verdine lab, which developed an all 
hydrocarbon staple which significantly increased peptide helicity.170  This led to the 
development of several hydrocarbon stapled peptides,171,172 some of which are in 
clinical trials.  In addition to increased helicity, hydrocarbon stapled peptides have 
been shown in some cases to have increased cell permeability173,174 and proteolytic 
stability.175 
 While the hydrocarbon staple has been used to successfully improve the drug-
like characteristics of peptides, hydrocarbon stapled peptides do not necessarily have 
enhanced binding or cell penetration.176  Additionally, hydrocarbon stapled peptides 
are sometimes not inherently more penetrant without other optimizations, such as 
adding positive charge.177  There are many other staple options which have been 
discussed in the literature.  Felix et al. reported the first lactam stapled peptides, which 
were analogues of growth hormone releasing factor 2 and demonstrated increased 
helicity and activity in cell culture,178 and the Fairlie lab optimized short lactam stapled 
peptides which were very helical in water and stable to trypsin proteolysis when 
compared to the linear peptides.179  Other staple options include cycloadditions, such 
as copper-catalyzed click reactions, formation of disulfides and thioethers, and a 
variety of two-component staples.180  It is likely that the ideal staple type is both 
system and sequence dependent. 
 Most of the examples of stapled peptides are mimicking highly ordered binding 
sites.  The goal of stapling is to achieve maximum helicity, sometimes over 95% 
helical even in the absence of the helix inducer trifluoroethanol.  Our stapled peptides 
will be mimicking disordered proteins, and even when they order upon binding the 
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bound peptide is about 50% helical.  One other stapled peptide, sTIP-04, has been 
reported for our system, and was compared to our other hydrocarbon stapled peptides 
in Chapter 2.  sTIP-04 was designed using molecular dynamics simulations to 
determine the favored conformational states of bound and free eIF4G based peptides.  
The peptides were then mutated to alter their conformational distribution to favor the 
bound state.  sTIP-04 introduced serine, glutamine, and leucine residues in place of 
aspartic acid and two phenylalanines.  It had a KD of 5 nM and was 63% helical.  sTIP-
04 uses a hydrocarbon staple which is 8 carbons long and has methyl groups in the α 
position of the stapling amino acids.1  Based on the success of this peptide, and the 
success of the hydrocarbon staple in the literature, our first 4E-BP1 stapled peptides 
were constructed using a hydrocarbon staple. 
 A few unstapled 4E-BP1 and eIF4G peptides have had some success in the 
literature.  A Tat-fused eIF4G1 peptide which was optimized for helicity showed 
activity in cell culture at 400 µM,109 and a gonadotropin releasing hormone (GnRH) 
conjugated 4E-BP1 peptide inhibited cap-dependent translation in GnRH receptor 
expressing cells and reduced tumor size in mice.181  These results are encouraging, 
although there is room for improvement since conjugated peptides are not ideal for 
probes or therapeutics.  The same group which developed sTIP-04 also found that, 
when making their phage display optimized sequence, the binding position of the 
peptide changed slightly with each modification.110  In this chapter, we use the 
information already known about the eIF4E-interacting peptides to design new 
peptides with different mutations and staple types with the goal of making a highly 
potent probe. 
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3.2 Structure activity relationships of linear 4E-BP1 and eIF4G peptides 
 We purchased a series of linear peptides to determine the effects of certain 
amino acid changes on peptide affinity and helicity.  Most of the peptides were based 
around the 4E-BP1 sequence, but some were based off of the eIF4G sequence.  The 
4E-BP1 peptides are shown in Table 3.1.  Our parent sequence, denoted as 4E-BP1 
(G49–N64) in Chapter 2, is called 4E-BP1–1 here.  We also made a peptide based off 
the sequence of the 4E-BP2 protein, which is called 4E-BP1–2.  This peptide had a 3–
fold improvement in activity over the 4E-BP1 sequence.  Removing the C-terminal 
asparagine and the N-terminal glycine and threonine (4E-BP1–3) resulted in equal 
activity as 4E-BP1–1, but re-instating that asparagine actually resulted in improved 
activity (4E-BP1–4).  Extending the sequence towards the C-terminus (4E-BP1–5) did 
not provide an increase in activity.   
Table 3.1 – Series of linear 4E-BP1 based peptides and their IC50s obtained with 
cat-ELCCA and their helicities determined with circular dichroism. 
4E-BP1 
(G
49–P66) 
G T R I I Y D R K F L M E C R N S P IC50 (nM) %Helicity 
% Helicity 
(40% TFE) 
1 G T R I I Y D R K F L M E C R N 
  
70 ± 20 16 37 
2   R I I Y D R K F L L D R R N   13 ± 3 13 35 
3   R I I Y D R K F L M E C R    70 ± 10 20 58 
4   R I I Y D R K F L M E C R N   41 ± 9 12 41 
5 
  
R I I Y D R K F L M E C R N S P 40 ± 7 14 44 
6   R I I Y S R K Q L M E C R N   12 ± 2 12 41 
7   R I I Y D R K F L M E A R    160 ± 40 7 35 
8   K K R Y D R K F L M E C R N   400 ± 100 8 28 
9      Y D R K F L M E C R N S P 8000 ± 4000 10 38 
10 G T R I I Y D R K F L L E C K N   500 ± 100 13 38 
11 G T R I I Y D R K F A A E C R N   dnb 10 32 
 
4E-BP1–6 attempts to make the same mutations to the 4E-BP1 sequence that 
are made in the sTIP-04 peptide.  These mutations led to a 3–fold increase in activity.  
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Mutation of the cysteine residue to an alanine resulted in only a 2–fold loss in activity 
(4E-BP1–7), which is interesting since the cysteine does not appear to participate in 
any hydrogen bonding with the surface of eIF4E in the crystal structure (Figure 3.1 A).  
We suspect that the cysteine residue may be making a thiol–pi interaction with the 
phenylalanine, stabilizing the helix.   
A B 
  
C  
 
Figure 3.1 – Crystal structure of the 
linear 4E-BP1 peptide (red sticks) 
bound to eIF4E (surface). (A) Potential 
cysteine–phenylalanine interaction, (B) 
leucine binding in a shallow hydrophobic 
pocket, and (C) methionine in a flat, 
hydrophobic region of the eIF4E surface.  
PDB ID 4UED. 
 
We wondered if adding the lysines and arginine to the N-terminus would give 
the 4E-BP1 peptide the kinetic advantage of the more disordered eIF4G peptide while 
maintaining the order of the 4E-BP1 peptides, but this hybrid (4E-BP1–8) had a 10–
fold loss in activity.  This could be because the N-terminal arginine and isoleucines 
were critical for activity in the 4E-BP1 sequence, because removing them (4E-BP1–9) 
resulted in the loss of nearly all activity, even though the canonical binding site 
(YXXXXLφ) was still present. 4E-BP1–10 is based off the 4E-BP3 protein 
sequence and is 7–fold worse than the corresponding 4E-BP1 sequence.  Finally, in 
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4E-BP1–11 we mutated the leucine and methionine residues to alanines.  These 
residues are in the canonical binding site and, as expected, their mutation completely 
removes all activity (Figure 3.1 B and C).   
 Interestingly, there is no correlation between helicity and IC50, with or without 
the helix inducer TFE.  However, some mutations did lead to interesting changes in 
conformation.  Since the helicity listed is the percent of the sequence that is helical, 
these numbers are dependent on the length of the peptide.  Therefore, the increased 
helicity of 4E-BP1–3 is likely in part simply because it is shorter.  However, 4E-BP1–9 
is of equivalent length and still contains the entire binding helix seen in the crystal 
structure, but is only half as helical as 4E-BP1–3.  4E-BP1–7 is also nearly 3–fold less 
helical as compared to the 4E-BP1 peptide of equivalent length, indicating that the 
cysteine contributes significantly to the helical nature of the peptide.  We also know 
that the serine and glutamine residues introduced in 4E-BP1–6 increase the activity of 
the peptide, but not the helicity, but the lysine and arginine residues in 4E-BP1–8 
reduce both the activity and the helicity.  Finally the 4E-BP1–10 sequence has similar 
helicity to 4E-BP1–1, but significantly reduced activity, and while 4E-BP1–11 does not 
inhibit, it still is somewhat helical. 
Table 3.2 – eIF4G based peptides with IC50s determined using cat-ELCCA 
and helicities from circular dichroism. 
eIF4G (K
608–
L
622
) 
K K R Y D R E F L L G F Q F IC50 (nM) %Helicity 
% Helicity 
(40% TFE) 
1 K K R Y D R E F L L G F Q F 160 ± 30 3 24 
2 K K Q Y D R E F L L D F Q F 900 ± 200 4 19 
3 K K R Y S R E F L L G F   450 ± 70 2 21 
4 K K R Y S R E Q L L G L   500 ± 100 4 13 
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 We next investigated the properties of a series of eIF4G peptides, shown in 
Table 3.2.  As seen in Chapter 2, the peptides were universally weaker inhibitors and 
less helical than the 4E-BP1 peptides.  eIF4G–2, which is based off of the sequence 
of the eIF4GII protein,182 has 5–fold reduced activity compared to eIF4G–1.  eIF4G–3 
was designed to further discern the importance of the mutations made in sTIP-04, but 
our linear version of sTIP-04 (eIF4G–4) had such poor activity that we couldn’t draw 
many conclusions.  All of the eIF4G peptides were much less helical than the 4E-BP1 
peptides, and they also had a decreased propensity for helicity with the addition of 
TFE.  Curves for IC50 and helicity are shown in Appendix B, Chapter 3 – Supplemental 
Information – IC50s and – CD. 
 
3.3 Structure activity relationships of stapled 4E-BP1 peptides 
 We hoped to use the information from our linear peptides to design potent 
stapled peptides.  Our first stapled peptides were hydrocarbon staples based off of 
Verdine’s work.  Dr. Lauren Mishra initiated the project with the synthesis of mHCS–1 
(shown in Table 3.3), and most of our early studies both in cells and in vitro were done 
with that peptide.  As such, most of our early SAR focused on that staple type.  
Unfortunately, the mHCS staple along with the HCS staple discussed in Chapter 2 had 
significant problems with their physical properties that hindered progress.  For 
instance, they were poorly soluble, and on several occasions formed a gel which was 
impossible to completely dissolve in any solvent.  Additionally, the methionine and 
cysteine residues, which we still have not managed to get rid of, made the peptides 
unstable in DMSO because they would quickly oxidize or dimerize.  The peptides also 
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aggregated in water, even at very low concentrations (Figure 3.2), and we think this 
aggregation was irreversible (or at least difficult to reverse) above a certain 
concentration, which caused our peptides to be sometimes active in cells, and 
sometimes not, potentially based on the concentration of the stock solution. 
mHCS–1 – 30.5 µM in water; radius = 63 nm 
 
mHCS–1 – 61 µM in water; radius = 5900 nm 
 
mHCS–1 – 122 µM in water; radius = 1300 nm 
 
Figure 3.2 – Aggregation of mHCS–1 visualized by dynamic light scattering. 
 Despite these issues, we were able to make a series of hydrocarbon stapled 
peptides, which are shown in Table 3.3.  Fortunately, the addition of the staple did 
improve the activity of the 4E-BP1–1 sequence by 2-fold (mHCS–1).  Unfortunately, 
very few of the trends observed with the linear peptides held true for the stapled 
peptides.  For instance, mHCS–2 is the stapled version of 4E-BP1–2, which is based 
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on the 4E-BP2 protein sequence.  While 4E-BP1–2 showed significant improvement 
over 4E-BP1–1, mHCS–2 is significantly worse than mHCS–1 (Figure 3.3 A).  
Furthermore, the truncation of the 4E-BP1 sequence in 4E-BP1–3 appeared to be 
tolerated, but its stapled version, mHCS–3, is 7–fold worse than mHCS–1 (Figure 3.3 
B).  Finally, introducing the serine and glutamine mutations in the linear sequence 
(4E-BP1–6) improved activity, but the stapled equivalent was 5–fold less active 
(Figure 3.3 C). 
A B 
  
 IC50 (nm)  IC50 (nm) 
4E-BP1–2 13 ± 3 4E-BP1–3 70 ± 10 
mHCS–2 160 ± 20 mHCS-3–E 250 ± 80 
  mHCS-3–L 220 ± 40 
C  
 
Figure 3.3 – Comparing IC50 curves 
for linear and stapled peptides. (A) 
4E-BP1–2 and mHCS–2, (B) 4E-BP1–3 
and mHCS–3 E and L, and (C) 4E-BP1–
6 and mHCS–6 E and L. 
 IC50 (nm)   
4E-BP1–6 12 ± 2   
mHCS–6-E 200 ± 100   
mHCS–6-L 160 ± 70   
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Table 3.3 – Series of mHCS peptides.  IC50s were determined with cat-ELCCA and 
helicities with circular dichroism.  * indicates that two isomers were isolated, but only 
data for the most active isomer is shown. NL = Norleucine 
mHCS  
 
 IC50 (nM) %Helicity 
% Helicity (40% 
TFE) 
1 G T R I I Y D R X F L M X C R N 30 ± 10 12 38 
2 G T R I I Y D R X F L L X R R N 160 ± 20 27  
3*   R I I Y D R X F L M X C R  220 ± 40 8 37 
4 G T R I I Y D R X F L NL X V R N 310 ± 70 11  
5 G T R I I Y D R X F L NL X S R N 130 ± 50 5  
6*   R I I Y S R X Q L M X C R N 160 ± 70 9 45 
 
  
 
    
7*   R I I Y D R X F * M X C R  430 ± 90 8  
   
 
    
8   R I I Y D R X F * M X C R  1000 ± 100 3 1 
      
 
    
9*   R I I Y D R X F L * X C R  300 ± 90 16 56 
   
 
     
10   R I I * D R X F L M X C R  2500 ± 800 16 44 
 
Our efforts to mutate the methionine and cysteine in order to improve peptide 
stability were unsuccessful.  mHCS–4, which mutated the cysteine to a valine and 
methionine to norleucine, had a 10–fold higher IC50 than mHCS–1.  Interestingly, this 
peptide’s KD was similar to mHCS–1 (Table 3.7), but it showed no activity in cells.  For 
mHCS–5, in which we mutated the cysteine to a serine and methionine to norleucine, 
had an improved IC50 but worse KD when compared to mHCS–4.  In the crystal 
structure, it appears that the cysteine is not hydrogen bonding with eIF4E, but is in fact 
interacting with the phenylalanine residue in the helix (Figure 3.1 A).  Perhaps 
mHCS–4 and 5 are unable to interact in the same manner.  These mutations need to 
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be made separately to further determine the effects of each amino acid.  Attempts to 
mutate the leucine residue failed (mHCS–7 and 8), and exchanging the methionine 
residue for O-methylhomoserine (mHCS–9) or the tyrosine for homotyrosine (mHCS–
10) also resulted in decreased activity. 
 Introducing the hydrocarbon staple did not generally have the expected effect 
on helicity.  mHCS–1 and 3 are less helical then their linear counterparts, although 
mHCS1 has improved activity and mHCS–3 has decreased activity.  In fact, nearly 
every peptide we made with the mHCS staple is less helical than the linear 4E-BP1 
peptides examined.  Many of the peptides with the most dramatic losses in helicity 
(mHCS 3, 5, and 8) did also have drastic losses in activity, but many of the less active 
peptides were also relatively quite helical (i.e. mHCS–2, 9, and 10). 
Table 3.4 – Comparison between early (E) and 
late (L) isomers for certain mHCS peptides. 
mHCS IC50 (nM) %Helicity 
% Helicity 
(40% TFE) 
3 E 250 ± 80 7 31 
3 L 220 ± 40 8 37 
6 E 200 ± 100 6 32 
6 L 160 ± 70 9 45 
7 E 1500 ± 300 28  
7 L 430 ± 90 8  
9 E 300 ± 90 16 56 
9 L 700 ± 80 9 25 
 
 Work on this staple was further complicated by the fact that with every one of 
these mHCS stapled peptides, we observed two peptides of the same mass with 
slightly different retention times in our crude peptide cleavage.  We suppose these two 
different peptides are two different isomers, and we suspect they are cis and trans 
isomers of the staple.  However, my colleague Dr. James Song found that the 
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peptides are too flexible in solution to prove this theory by NMR.  Regardless, the 
presence of the two peptides made purification extremely difficult, because we needed 
to separate the isomers from each other, as well as from all of the other impurities 
from synthesis.  The fact that the peptides smeared on the HPLC column under all 
conditions didn’t help.  Even so, we did manage to at least isolate one pure isomer 
from each synthesis, and in some cases we were able to isolate both.  Table 3.3 
shows the most active isomer that we isolated in the case where we got both, but 
Table 3.4 compares the two isomers side-by-side. 
 Since we were unable to determine difference between the two isomers, we 
simply referred to them as “early” or E and “late” or L based on their retention time.  In 
some cases, the isomers were nearly identical both in terms of activity and helicity (for 
instance, mHCS 3 and 6).  In other cases, the peptides were quite different.  mHCS–7-
E and mHCS–10-L are both more helical and less active than their counterparts, but 
mHCS–9-E was more helical more active than mHCS–9-L. 
Table 3.5 – Series of OAlSer and HCS peptides. 
OAlSer  
 
 IC50 (nM) %Helicity 
% Helicity (40% 
TFE) 
1 G T R I I Y D R X F L M X C R N 28 ± 7   
HCS  
 
    
1 G T R I I Y D R X F L M X C R N 5 ± 2 44 83 
2 G T R I I Y D R X F A A X C R N 8000 ± 7000 35 64 
3   K K R Y D R X F L L X F   6000 ± 1000 3 20 
4   K K R Y S R X Q L L X L 
  
23 ± 7 38 58 
 
 While the mHCS peptides were initially very promising, we elected to explore 
other staple types in order to mitigate the problems with solubility and purification.  We 
made an O-Allyl Serine stapled peptide, OAlSer–1, shown in Table 3.5.  This peptide 
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was even less soluble than mHCS–1, and it seemed to degrade very quickly, so we 
instead proceeded with an HCS staple, discussed in Chapter 2 and shown in Table 
3.5.  The HCS staple resulted in a significant increase in helicity for the 4E-BP1 
peptides and for sTIP-04.  Also, HCS–1 had significantly better activity than 4E-BP1–1 
and mHCS–1 (Figure 3.4), had the best in vitro activity of any peptide we had tested 
so far, it was active in our cell assays, it got into cells, and it did not form two isomers, 
so it was (relatively) easy to purify. 
 
Figure 3.4 – Comparison of IC50 
curves between 4E-BP1–1, mHCS–1, 
and HCS–1. 
 IC50 (nm) 
4E-BP1–1 70 ± 20 
mHCS–1 30 ± 10 
HCS–1 5 ± 2 
 
The HCS peptides solved a lot of our problems, but they still were poorly 
soluble, they aggregated in solution, and sometimes suffered from poor reproducibility.  
Additionally, the amino acid used to make them was very difficult to make and very 
expensive to buy.  We therefore tried lactam staples to see if we could maintain the 
excellent activity of HCS–1 while improving upon the physical properties of the 
peptides.  We made two orientations of the lactam staple, LacA and LacB, shown in 
Table 3.6.  At this point, we also elected to focus on the shorter 4E-BP1 sequence in 
hopes that we could decrease the cost and labor associated with making these 
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peptides.  LacA–1 had similar activity as mHCS–1, but worse activity than HCS–1.  
However, it did have better solubility (by about 4-fold), so this result was encouraging.  
We also tried adding an N-methylated aspartic acid, shown in LacA–2, with the hopes 
of improving its proteolytic stability.  However, this mutation significantly reduced 
activity.   
Table 3.6 – Series of lactam stapled peptides, LacA and LacB. 
LacA  
 
 IC50 (nM) %Helicity 
% Helicity (40% 
TFE) 
1   R I I Y D R X F L M X C R  27 ± 5 19 55 
    
 
    
2   R I I Y * R X F L M X C R  300 ± 200 14 34 
LacB    
 
    
1   R I I Y D R X F L M X C R  8 ± 3 40 80 
2   R I I Y S R X Q L M X C R N 7 ± 4 20 47 
 
 LacB–1, on the other hand, had similar activity as HCS–1 despite its shortened 
sequence.  It also had a 3–fold improvement in in vitro activity over LacA–1.  While we 
wondered if the significant increase in activity was due to the significantly increased 
helicity, we found that the serine and glutamine mutant, LacB–2, had equal potency as 
LacB–1 but similar helicity to LacA–1.  We therefore used SPR to collect kinetic data 
for all of the stapled peptides to help determine the reasons for the differences in 
activity that we saw. 
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3.4 Kinetic analysis of 4E-BP1 stapled peptides 
 When examining the stapled peptide kinetics, we found some surprising trends 
(Table 3.7). For instance, the KD does not correlate very well with the IC50.  There is 
also no strong correlation between ka or kd and IC50.  However, in the case of the 
mHCS isomers, the isomer with the faster off-rate has a worse IC50.  In general, it 
seems that the kinetics of interaction and their effect on inhibition is peptide specific.  
In some cases, the off-rate appears to drive inhibition, but in others the on-rate seems 
to be the bigger contributor.  Sensorgrams for all peptides are found in Chapter 3 – 
Supplemental Information – SPR. 
Table 3.7 – Binding kinetics of the mHCS and OAlSer peptides 
determined by SPR. 
mHCS Ka (M
-1
s
-1
) Kd (s
-1
) KD (nM) IC50 (nM) 
1 4.69 ± 0.02 x 10
5
 11.27 ± 0.02 x 10
-3
 24.0 ± 0.1 30 ± 10 
2 2.7 ± 0.4 x 10
5
 9 ± 1 x 10
-3
 36 ± 4 160 ± 20 
3-E 0.773 ± 0.002 x 10
5
 6.66 ± 0.01 x 10
-3
 86.2 ± 0.3 250 ± 80 
3-L 0.732 ± 0.001 x 10
5
 5.276 ± 0.008 x 10
-3
 72.0 ± 0.2 220 ± 40 
4 7.22 ± 0.03 x 10
5
 21.26 ± 0.02 x 10
-3
 24.9 ± 0.1 310 ± 70 
5 0.2 ± 0.1 x 10
5
 28 ± 3 x 10
-3
 2000 ± 120 130 ± 50 
6-E 1.34 ± 0.01 x 10
5
 4.62 ± 0.2 x 10
-3
 35 ± 5 200 ± 100 
6-L 1.05 ± 0.09 x 10
5
 3.6 ± 0.2 x 10
-3
 35 ± 6 160 ± 70 
7-E 3.0 ± 0.8 x 10
5
 18 ± 3 x 10
-3
 65 ± 7 1500 ± 300 
7-L 0.1947 ± 0.0006 x 10
5
 8.41 ± 0.02 x 10
-3
 432 ± 1 430 ± 90 
9-E 1.80 ± 0.02 x 10
5
 5.17 ± 0.02 x 10
-3
 28.8 ± 0.5 300 ± 90 
9-L 5.43 ± 0.07 x 10
5
 12.5 ± 0.4 x 10
-3
 23 ± 1 700 ± 80 
10 0.32 ± 0.04 x 10
5
 5 ± 1 x 10
-3
 180 ± 60 2500 ± 800 
OAlSer     
1 0.8 ± 0.2 x 10
5
 5.1 ± 0.7 x 10
-3
 80 ± 20 28 ± 7 
 
 For the remaining peptides in Table 3.8, the trend is more consistent.  HCS–1 
has a very fast on rate and a rather slow off-rate, which explains why that compound 
is such a strong inhibitor in vitro.  sTIP-04 (HCS–4) has a similar KD to HCS–1, but a 
weaker IC50.  This could potentially be explained by its slower on-rate.  LacA–1 has 
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similar kinetic trends as compared to HCS–1, and LacB–1 has an on-rate that is twice 
as fast as HCS–1’s, which results in a KD of 2 nM.  This data confirms that we have 
effectively designed a stapled peptide with equivalent potency as HCS–1 but with 
superior solubility.  As a bonus, LacB–1 is also much easier to purify because it does 
not smear on the column.  With this data in hand, we proceeded to test our best 
peptides in cell assays to determine how to proceed. 
Table 3.8 – Binding kinetics for the HCS and lactam stapled peptides. 
HCS Ka (M
-1
s
-1
) Kd (s
-1
) KD (nM) IC50 (nM) 
1 15 ± 2 x 10
5
 5 ± 4 x 10
-3
 4 ± 3 5 ± 2 
3 3.3 ± 0.1 x 10
5
 30 ± 4 x 10
-3
 90.0 ± 0.3 6000 ± 1000 
4 8.3 ± 0.5 x 10
5 
5.2 ± 0.1 x 10
-3
 6.3 ± 0.4 23 ± 7 
LacA     
1 5.82 ± 0.06 x 10
5
 4.18 ± 0.03 x 10
-3
 7.2 ± 0.1 27 ± 5 
2 1.5 ± 0.2 x 10
5
 10.9 ± 0.8 x 10
-3
 74 ± 3 300 ± 200 
LacB     
1 30.9 ± 0.2 x 10
5
 6.87 ± 0.01 x 10
-3
 2.23 ± 0.01 8 ± 3 
 
3.5 Cell activity of 4E-BP1 stapled peptides 
 The cell data for the HCS peptides is shown in Chapter 2.  All cell data 
(excluding the CAPA assay in section 3.6) was collected by Arya Menon.  Cells were 
treated with the peptide for 6 hours and then lysed.  Resin-bound m7GDP was added 
to bind to the eIF4E.  The resin was boiled and a Western blot was used to visualize 
the levels of 4E-BP1 and eIF4G pulled down.  Figure 3.5 shows that LacA–1 was not 
active in cells, despite the fact that its IC50 is equivalent to mHCS–1, which is active in 
cells.  LacB–1 did inhibit the pull-down of 4E-BP1 and eIF4G in Tamoxifen resistant 
MCF7 cells and in MDA-MB-231 cells.  We also confirmed that the effect was dose 
dependent in MDA-MB-231 cells, which is shown in Figure 3.6.  Interestingly, the 
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effect on eIF4G appears to be less pronounced than the effect on 4E-BP1.  This could 
be due to the levels of the eIF4G and 4E-BP1 proteins in the cell. 
 
Figure 3.5 – Pulldown data for LacA–1 and LacB–1 in Tamoxifen 
resistant MCF-7 and MDA-MB-231 cells. 
  
 
Figure 3.6 – Concentration dependence in pulldown assay for LacB–1 in MDA-
MB-231 cells. 
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3.6 Cell penetration of lactam stapled peptides 
 The cell penetration of the HCS peptides was measured by imaging of FITC-
labeled peptides as shown in Chapter 2.  However, the FITC tag decreased the 
solubility of these peptides significantly, so we decided to pursue other options for 
measuring cell penetration.  LacA–1, LacB–1, and LacB–2 were all tested in a 
Chloroalkane Penetration Assay (CAPA) developed by the Kritzer lab and run by 
Kirsten Deprey.183  In brief, Hela cells expressing the Halotag protein in the cytoplasm 
were treated with peptide with a chloroalkane linker on the N-terminus for 4 hours.  
The cells were then treated with a fluorophore with the same chloroalkane linker.  The 
assay measured the decrease in signal from the fluorophore to obtain a CP50, or the 
concentration at which 50% of the fluorescent signal is present.  LacA–1, LacB–1, and 
LacB–2 were tested, as well as a LacB–1 peptide with the addition of three arginine 
residues on the amino terminus.  The results of this assay are shown in Figures 3.7 
and 3.8. 
 The cell penetration of our peptides is within the range of other well-known 
peptides.  When tested in the same assay, the hydrocarbon stapled peptide Bim–
SAHB172 had a CP50 of 0.65 µM, Arg9 had a CP50 of 0.3 µM, and TAT had a CP50 
value of 3.1 µM.  This data indicates that our peptides successfully penetrate the cell 
without the use of a tag.  Interestingly, LacB–1 is 6 times more cell penetrant than 
LacA–1, which likely explains why LacB–1 shows activity in our eIF4E pulldown assay 
while LacA–1 does not.  The addition of three arginines to the amino terminus of 
LacB–1 did not increase cell penetration, which is likely because LacB–1 is already 
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equally penetrant as Arg9.    Finally, while LacB–2 has an encouraging IC50 value, it is 
3–fold less penetrant than LacB–1. 
 
Figure 3.7 – Cell-penetration of lactam stapled peptides, as determined using 
the CAPA assay. 
 
 LacB-1 LacB-1-
RRR 
LacA-1 LacB-2 
Figure 3.8 – Percent uptake of peptide at 
0.74 µM, as determined by CAPA. 
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 Figure 3.8 shows that the peptide is entering the cell, at least somewhat, at the 
concentrations tested in our cap pulldown assay.  However, the difference in 
penetration between the peptides is quite surprising.  We cannot at this time explain 
the difference in penetration between LacB–1 and LacA–1.  LacB–1 is twice as helical 
as LacA–1, however, so we hypothesize that LacB–1 is more efficient at shielding its 
amide backbone to travel through the membrane.  This process could also be involved 
in release from the endosomes once inside the cell.  We are currently solving the 
solution NMR structure of LacB–1 and LacA–1 to help explain the difference in cell 
uptake. 
 
3.7 Conclusions 
 We found that the mHCS staple is very difficult to work with, at least with the 
4E-BP1 sequence, due to its tendency to form two different isomers.  While the more 
constrained HCS staple did not form multiple isomers, it was still very hydrophobic and 
the peptides were poorly soluble and tended to aggregate in solution.  Even the 
synthesis of the hydrocarbon stapled 4E-BP1 peptides was difficult, and it was 
necessary to use low loading resin to avoid aggregation, even in organic solvent when 
most of the amino acids were protected.  This is in contrast to the sTIP-04 peptide, 
which is relatively very soluble in water, has a high-yielding synthesis, and does not 
appear to aggregate.  This could potentially be because the sTIP-04 peptide is shorter 
(12 amino acids), but we found that the mHCS truncated 4E-BP1 peptide (mHCS–3), 
which is 13 amino acids long, was not active.  Based on this data, we can say that the 
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ideal staple type depends on sequence, and while the hydrocarbon staple can pose 
problems due to hydrophobicity, it does not always cause problems. 
 With regards to the 4E-BP1 peptides, we found that the lactam staple 
dramatically improved the physical properties of the peptides while maintaining the 
strong binding affinity and inhibition.  This is not surprising, because the lactam 
stapled peptide is much less hydrophobic than the hydrocarbon staples.  However, we 
were not expecting to see such a large difference between the LacA and LacB 
staples.  While their affinities were similar (7 nM vs. 2 nM, respectively), the difference 
in helicity (19% vs. 40%), cell activity, and cell penetration were dramatic. 
 With regards to cell penetration, a balance of helicity, hydrophobicity and PI are 
required for optimal cell uptake.  Bird et al report that for a hydrocarbon stapled 
peptide, an ideal isoelectric point (PI) is between 8.8 and 9.34, and the ideal helicity is 
between 61 and 86%.  Finally, excessive hydrophobicity and positive charge can lead 
to nonspecific membrane disruption rather than membrane penetration.173  Both of 
these peptides have the same PI and hydrophobicity; the PI is 9.08, well within the 
ideal range, and the Log P (consensus Log P, calculated using SwissADME) is -2.05, 
which is not excessively hydrophobic.  The only physical difference between the two 
peptides is their helicity; while neither peptide is within the ideal range, LacB-1 is 
much more helical than LacA-1.  While maximizing alpha helicity does not guarantee 
optimal biochemical or biological activity,175 it seems that for these peptides the 
difference in cell uptake is related to the helicity or conformation of the peptides. 
 Still, it is surprising that changing the orientation of the lactam staple led to a 2–
fold increase in helicity.  However, this has been observed before in the literature.  
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There are many examples in which only one orientation was tested (usually the LacA 
orientation),184–186 but Houston et al directly compared E to K staples (as in LacB) with 
K to E staples (as in LacA).  They found that an i, i + 4 LacA stapled peptide was 
actually less helical (29%) than its linear counterpart (61%).  Furthermore, the 
equivalent LacB stapled peptide was more helical than the linear, at 71%.187  While 
the linear sequence in this case was more helical than our peptides (due to 
stabilization by salt bridges), this trend is consistent with what we have seen.  They 
hypothesize that the orientation of the lactam bridge in the LacA staple may have a 
destabilizing interaction between the lactam carbonyl and the backbone.  We have 
taken NMRs of our peptides and are currently solving the structure to see if that is the 
case. 
 
3.8 Materials and Methods 
Peptide Synthesis 
Solid Phase Peptide Synthesis 
Coupling and Fmoc Deprotection 
Peptides were synthesized using Solid Phase Peptide Synthesis (SPPS) on Rink-
Amide Resin.  Reactions were done in a fritted syringe which was placed on a shaker 
during incubations.  The resin was washed thoroughly between each step with four 
washes of 10 mL of DMF, followed by one wash of 10 mL DCM, and one final wash of 
10 mL of DMF.   
The loading of the resin was artificially lowered by using excess resin (1g for 0.2 mmol 
scale) and coupling only 1.5 equivalents of the first amino acid.  The remaining un-
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reacted amines were acetylated, and then the synthesis was completed as usual.  
Each amino acid (excluding amino acids used in stapling, which were coupled only 
once using 3 equivalents) was double coupled using 5 equivalents of amino acid for 2 
hours for the first coupling and 1 equivalent for 1 hour for the second.  HBTU was 
used as a coupling reagent in a 1:1 ratio with amino acid and 10 equivalents of DIPEA 
in NMP.  FMOC deprotection was performed with two 10 minute washes with 20% 
piperadine and 90 mM HOBt in NMP.   
Acetylation 
All peptides were acetylated at their amino terminus and amidinated at their carboxy 
terminus.  Acetylation was performed by mixing 1.6 mL of DIPEA with 0.9 mL of Acetic 
Anhydride and 4 mL of NMP.  The solution was incubated with the resin for 5 minutes. 
Olefin Metathesis 
Olefin metathesis was performed after all amino acids had been added to the resin, 
but before the final FMOC deprotection by adding 20 mg of Grubbs I catalyst to 10 mL 
of dichloroethane and the resin.  The mixture was bubbled with Nitrogen for at least 2 
hours.  This process was repeated for a total of two times.  Stapling was confirmed 
with mass spec. 
Lactamization 
The lactam stapled peptides were synthesized using Fmoc-Lys(Mtt)-OH and Fmoc-
Glu(O-2-PhiPr)-OH to construct the staple.  After the addition of the second stapling 
amino acid (lysine for LacA and glutamate for LacB), the resin was equilibrated with 
DCM.  The resin was then washed with four 2 minute washes with 2.25% TFA and 5% 
TIPS in DCM.  The resin was then washed four times with DCM, once with DCM with 
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2% DIPEA to neutralize the resin, and then washed with DMF and DCM as usual.  The 
amino acid side chains were stapled with 6 equivalents of Pybop and 10 equivalents 
of DIPEA in NMP for at least 2 hours. 
Cleavage 
Cleavage was performed with TFA/Phenol/Thioanisol/Water/Triisopropylsilane in a 
ratio of 83/6.25/4.2/4.2/2 for 3 hours.  The peptide was precipitated from the cleavage 
with ice cold ether, collected by filtration, and washed with 40 mL of cold ether. 
Purification 
The crude peptide was purified using reverse phase HPLC with 0.1% Formic Acid in 
Acetonitrile or water.  In cases where this was insufficient, purification was repeated 
using 0.1% Formic Acid in Methanol or water.  Pure fractions were lyophilized, 
dissolved in 50% acetic acid and water, and lyophilized again.  The final peptide was 
dissolved in water or a combination of water and DMF, filtered, and the concentration 
was determined by amino acid analysis.  The dissolved peptide was aliquoted and 
stored at -80°C. 
Circular Dichroism 
Circular Dichroism was completed using the same method described in Chapter 2. 
Cat-ELCCA 
Cat-ELCCA was completed using the same method described in Chapter 2. 
SPR 
SPR was performed as described in Chapter 2. 
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Chapter 4 
Future Directions 
 
4.1 Additional structural modifications for lactam stapled peptides 
Modifications for Chemical Stability 
 The 4E-BP1 sequence contains both a cysteine and a methionine.  These 
residues are difficult to work with due to their tendency to dimerize and oxidize.  We 
have optimized peptide storage conditions to minimize this occurrence.  For instance, 
the peptide is kept under acidic conditions until the final pure peptide is dissolved in 
water.  At that point, the peptide is aliquoted and frozen at -80°C.  Even still, peptides 
stored at -80°C have been observed to dimerize over the course of a year.  Therefore, it 
is important to continue our efforts to mutate the cysteine and methionine residues away 
to improve the chemical stability of the peptides. 
 Since we have observed a significant difference in peptide sequence activity with 
different staple types, some modifications which we tried before would be worth trying 
again with the lactam stapled peptide.  These include the valine and serine as 
substitutes for cysteine, and O-methylhomoserine and norleucine as substitutes for 
methionine, which have all been tried with the mHCS staple.  Additionally, the 4E-BP2 
protein sequence does not have a cysteine or methionine residue, and while the mHCS 
version of this peptide is not active, it is possible that the lactam staple will be active.  
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Additionally, our lab has made considerable efforts towards the synthesis of a difluoro 
amino acid to act as a mimetic of cysteine.  While our attempts so far have failed, this 
goal may still be worth pursuing, because a difluoro amino acid would have similar size 
and hydrophobicity as cysteine.  Finally, a variety of other hydrophobic amino acids 
could be tried at both positions.  Some of the potential cysteine and methionine 
replacing amino acids are shown in Table 4.1. 
Table 4.1 – Potential replacements for the unstable cysteine and methionine 
residues. 
 
 
  
 
Cysteine  Valine Serine 
Arginine – 
from 4E-BP2 
     
  
 
 
H2N
OH
O
F
F
 
  Norvaline Amino Butyric Acid Difluoro Amino Acid 
     
     
 
 
   
Methionine  O-Methylhomoserine Norleucine 
Leucine –  
from 4E-BP2 
     
  
   
  Isoleucine Cyclobutyl Alanine Cyclopropyl Alanine 
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Modifications for Proteolytic Stability 
 We hope that the staple will provide some stability to protease activity, which is 
the primary method of metabolism for peptides.  However, once we determine the half-
life and sites of metabolism of the peptide, it is likely that further modification will be 
necessary to increase its stability.  Several different methods could be used, including 
introducing methyl groups at the sites of cleavage, the use of D-amino acids, or the use 
of other unnatural amino acids.  
 
Figure 4.1 – Chymotrypsin cleavage sites in LacB-1. 
 
 Chymotrypsin, which is a digestive protease produced in the pancreas and found 
in the duodenum, has two known cleavage sites on our lead peptide, LacB-1, which are 
shown in Figure 4.1.  Chymotrypsin cleaves on the C-terminal side of aromatic 
residues, including phenylalanine and tyrosine, which are both present in our 
sequence.188  While we hope the staple will shield the phenylalanine site, tyrosine is still 
exposed.  We already made an N-methyl aspartic acid substituted peptide (LacA-2), but 
found that this peptide was less active than the un-methylated peptide.  We also made 
the homotyrosine substituted peptide (mHCS-10), which also significantly lost activity, 
although this peptide was not made with the lactam staple.  If this site is shown to be 
metabolically unstable, we will try D-tyrosine and D-aspartic acid to see if those 
substitutions are tolerated.  Unfortunately, the tyrosine residue is part of the consensus 
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sequence and is conserved across both the 4E-BP and eIF4G isoforms, so it will likely 
be difficult to remove.  At this stage, it is most important to first identify the sites of 
metabolism, and then use these strategies to mask them. 
 
4.2 Pharmacokinetic studies of lactam stapled peptides 
While small molecules are typically metabolized in the liver, peptides are 
primarily metabolized in the kidneys.189  Additionally, serum and tissue proteases and 
nonspecific protease activity are the primary methods of degradation, as opposed to 
CYPs for small molecules.  Peptides are typically rapidly cleared and poorly bioavailable 
(less than 2%), which is why we introduce unnatural modifications (such as the staple) 
to improve their stability.190  Considering this information, it is unlikely that a microsomal 
stability assay, which uses liver enzymes to predict in vivo clearance, would be 
particularly helpful in our case. 
Measuring the serum and plasma stability of our peptides is a better in vitro 
model for metabolism.  However, a recent study indicated that peptides are actually 
more stable in whole blood than in serum or plasma, and that serum stability assays 
can mislead a researcher into modifying a site of instability in vitro that is not relevant in 
vivo.191  On the other hand, the use of anticoagulants, such as EDTA, can deactivate 
some proteases present in the whole blood.  The most ideal method for measuring 
stability in vitro would therefore be to use whole blood stability without the use of 
anticoagulants.191  However, we will be working with the PK core at the University of 
Michigan to collect this data and will consult with them to determine the best method 
according to their expertise and available resources.  This in vitro data will be used to 
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determine the most likely sites of hydrolysis or other modification, and the methods 
discussed in section 4.1 will be used to address the sites of instability.  At that point, the 
use of in vivo models for metabolic stability will be more appropriate. 
 
4.3 Pulldown experiments with stapled peptides 
 The stapled peptides bind to eIF4E with high affinity, but they still may potentially 
have other targets in the cell.  For instance, several years ago Arya Menon did a 
Western blot to observe the effects of mHCS-1 treatment on 4E-BP1 phosphorylation.  
We observed what appeared to be inhibition of 4E-BP1 phosphorylation, which is not 
consistent with a peptide that is only inhibiting the eIF4E–eIF4G (or eIF4E–4E-BP1) PPI 
(Figure 4.2).  Furthermore, we did not observe inhibition of S6K phosphorylation, which 
would be expected if the peptide was inhibiting mTORC1.  Unfortunately, we have not 
had the chance to repeat this study using any of the other peptides, and prior to making 
a pulldown probe we would confirm that this effect repeats with the appropriate 
peptides.  However, if there is a difference between different peptides, we would make 
pulldown probes of both to compare.  These probes would consist of the peptide 
conjugated to a biotin, which would allow the live cells to be treated and lysed, at which 
point streptavidin beads would be added to the lysate to pulldown the probe. 
 Synthetically, it would be easiest to introduce a biotin on the amino terminus of 
the peptide.  However, we could also introduce it on the carboxy terminus using 
Mtt(lysine), which is protected with a very acid sensitive protecting group, as the first 
residue in the sequence.  The resin bound peptide would be treated with dilute TFA and 
then the biotin linker would be added using normal coupling conditions.  In the case of 
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the lactam stapled peptides, the biotin and any linker would have to be added early in 
the synthesis, because the same acid sensitive protecting group is used to make the 
staple on resin.  Even for hydrocarbon stapled peptides, it would be ideal to add a C-
terminal biotin early in the synthesis to avoid accessibility problems. 
A 
 
B 
 
C 
 
Figure 4.2 – The effect of peptide treatment on (A) 4E-BP1 phosphorylation and 
(B) S6K phosphorylation.  MDA-MB-231 cells were treated with mHCS-1 for 6 hours.   
Section (C) shows the mTORC1 mediated phosphorylation of both proteins. 
 
 The biotin could be added directly, or a short linker could be included.  The 
addition of a PEG linker would improve the solubility of the peptide, but early data 
indicates that PEG reduces the activity of our 4E-BP1 peptides, so a β-alanine linker 
should also be considered.  The linker and placement would first be optimized for 
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peptide activity before attempting any pulldown assay.  We would also have to consider 
the effect of a biotin on the cell penetration of our peptides.  Finally, it would be ideal to 
have completed in vitro PK studies prior to this experiment and optimized the peptide 
sequence to minimize metabolism, because the study will be ineffective if the biotin is 
cleaved off of the active portion of the peptide. 
 Initial pulldown results would be analyzed by Western blot.  Confirming that the 
peptide pulls down eIF4E is critical to confirm that the peptide is still active in cells.  
Additionally, the biotin conjugated peptide should still perform similarly in our eIF4E 
pulldown assay.  If the probe passes these tests, we can blot for mTOR and other 
potential 4E-BP1 phosphorylating kinases.  Finally, we can use proteomics to assist in 
the identification of unexpected targets of the peptides. 
 An additional use of the pulldown probe could be to identify off-target 
mechanisms of toxicity.  When Arya Menon tested HCS-1 and sTIP-04 in a cell titer glo 
assay, which measure cell viability, she found that sTIP-04 is much more toxic than 
HCS 4E-BP1.  As expected, the negative control HCS 4E-BP1 LM->AA did not kill cells.  
These results are shown in Figure 4.3 A-C.  Figure 4.3 D also shows that the sTIP-04 
toxicity is not due to nonspecific membrane disruption.  Based on the fact that sTIP-04 
and HCS-1 have similar behavior in our eIF4E pulldown assays, we hypothesize that 
either sTIP-04 has an off-target effect which is mediating its toxicity, or HCS 4E-BP1 
has an off-target effect which is rescuing cells.  In either case, pulldown probes for each 
peptide could be used to identify additional targets using proteomics to analyze the 
pulldown results.  This information could be used to explain the observed toxicity and to 
design a better eIF4E–eIF4G PPI inhibitor.  
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A 
 
B 
 
C 
 
D 
 
Figure 4.3 – Cell viability measured by a Cell Titer Glo assay after treatment with 
(A) sTIP-04, (B) HCS 4E-BP1, and (C) HCS 4E-BP1 LM->AA.  (D) An LDH assay 
indicates that sTIP-04 does not cause membrane leakage. 
 
4.4 Relationship between staple type and cell penetration 
 We found that the cell penetration of the 4E-BP1 peptides was significantly 
affected by the orientation of the lactam staple.  It would therefore be interesting to 
compare multiple staple types with one 4E-BP1 sequence to determine the effect on cell 
penetration.  The FITC labeled peptides described in Chapter 2 were not very soluble, 
but the modifications required for the CAPA assay developed by the Kritzer lab183 are 
better tolerated.  This assay would therefore be ideal for measuring the cell penetration 
of these peptides. 
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 Modifications to the length of the staple and the position of the amide bond would 
be made first.  Additionally, different staple stereochemistries could be used for any of 
the staples types.  Hydrocarbon, O-allyl serine, triazole, and thioether staples would all 
be relatively simple to introduce.  Two component stapling could be used as well, 
although it may be best to see the effect of the basic staples first.  The staple position is 
not very flexible due to the length of the 4E-BP1 helix, but some modifications could be 
made.  For instance, making an i, i +3 staple between the lysine and methionine 
residues may be tolerated.  Even if the peptides lose affinity for eIF4E, they can still be 
used to make observations about the effect of a modification on cell penetration.  All 
peptides would be analyzed for helicity with and without TFE and would be tested in the 
CAPA assay for cell penetration.  Table 4.2 outlines a list of initial stapling ideas to try 
for this experiment. 
Table 4.2 – Potential staple positions and types for cell penetration experiments. 
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4.5 Development of a functionalized staple  
We had tried to shift the position of the hydrocarbon staple one step towards the 
amino terminus, replacing arginine and methionine residues. This would cause the 
staple to rest against the surface of the protein. However, this stapled peptide showed 
no activity in cells (data not shown), which we presumed was due to the disruption of an 
arginine-aspartic acid salt bridge between the peptide and the surface of eIF4E. 
However, a staple which maintains the arginine functional group may be more 
successful. We made some attempts to synthesize such a staple using olefin 
metathesis and lactamization, which were both chemistries that we were already 
familiar with.  However, these attempts were unsuccessful, and are shown in Figure 
4.4. 
 
Figure 4.4 – Unsuccessful attempts towards designing an arginine 
functionalized stapled peptide. 
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 An alternative strategy to making a functionalized staple could involve 
synthesizing the entire staple in solution and then adding it to the peptide on resin.  This 
would involve the use of many protecting groups so that the staple could be added in 
the right order.  A proposed synthesis is shown in Figure 4.5, and the method for 
incorporating the staple into the resin-bound peptide is shown in Figure 4.6. 
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Figure 4.5 – Proposed scheme for the synthesis of a functionalized staple in 
solution. 
 
Figure 4.6 – Proposed scheme for the incorporation of the solution synthesized 
functionalized staple into the resin-bound peptide. 
74 
 
4.6 Conclusions 
 The work presented in this chapter will hopefully take a promising lead and turn it 
into a useful probe.  Optimization for chemical and metabolic stability will minimize the 
controllable problems associated with peptide therapeutics.  Ideally, we will be able to 
find tolerated substitutions for the oxidizing residues, which will improve the shelf life of 
this peptide and make it much easier to work with.  Additionally, identifying the most 
likely sites of metabolism will enable us to modify those sites for stability.  If basic 
modifications (such as N-methylation, homo-amino acids, or D-amino acids) are not 
tolerated, we can try more drastic measures, such as synthesizing the entire peptide 
using D-amino acids.  In this case, we would likely need to re-optimize the staple length, 
type, and position. 
 With regards to off-target effects, our peptide could still be effective if it inhibits 
4E-BP1 phosphorylation as well as the eIF4E–eIF4G PPI.  However, it would be useful 
to know what, if any, other protein is being affected.  This would allow us to learn more 
about the mechanisms of 4E-BP1 phosphorylation, and to potentially target that 
pathway deliberately.  Separately, finding the mechanism of toxicity of the sTIP-04 
peptide would be useful in the validation of the eIF4E–eIF4G PPI as a cancer target; if 
either peptide has significant off-target effects, it will not be a good candidate for 
validation. 
 The stapled peptide field has advanced significantly over the last 20 years, but 
there is still more room for advancement, particularly with intrinsically disordered parent 
sequences.  Optimization of the staple and cell penetration will be useful in our work 
towards developing a stable and highly active probe, but it can also provide interesting 
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information regarding the benefits of certain staple types over others.  Of particular 
interest will be if the cell penetration continues to correlate with helicity, or if 
hydrophobicity or some other property seems to be more important.  This will be 
particularly interesting to see with the non-hydrocarbon staples, because while the 
hydrocarbon staple type has been well studied and often successful, it is clearly not a 
universal approach.   
Lastly, most of the available staple types to date rely on chemistries which can 
be performed on resin.  The synthesis of the staple in solution would allow for more 
complicated functionalization, such as the arginine functional group presented here.  
However, this chemistry could likely be tuned to introduce many different kinds of 
functional groups in peptide staples, which would allow for the development of more 
complex peptide mimics. 
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Appendix A 
Chapter 2 – Supplemental Information 
IC50 Curves for Peptides 
4E-BP1 Peptides 
4E-BP1 Linear Peptides 
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4E-BP1 Stapled Peptides 
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eIF4G Peptides 
eIF4G Linear Peptides 
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eIF4G Stapled Peptides 
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CD Curves for Peptides 
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SPR Curves for Peptides  
Data for Kinetic Analysis 
Table A2.1 – Kinetic binding data at a variety of temperatures for linear peptides 
determined by SPR. 
 Temperature (°C) Ka (M
-1
s
-1
) Kd (s
-1
) KD (nM) 
4E-BP1 (G
49
-N
64
) 10 0.4 ± 0.2 x 10
6
 8.2 ± 0.8 x 10
-3
 17 ± 4 
 15 0.5 ± 0.2 x 10
6 
9.6 ± 0.9 x 10
-3
 17 ± 2 
 20 0.6 ± 0.3 x 10
6
 13 ± 2 x 10
-3
 21 ± 7 
 25 0.8 ± 0.3 x 10
6 
21 ± 4 x 10
-3
 26 ± 6 
 30 1.3 ± 0.4 x 10
6
 32 ± 5 x 10
-3
 24 ± 5 
4E-BP1 (R
51
-N
64
) 10 1.47 ± 0.03 x 10
6
 6.9 ± 0.5 x 10
-3
 4.7 ± 0.5 
 15 1.0 ± 0.1 x 10
6 
9.3 ± 0.7 x 10
-3 
9 ± 1 
 20 1.2 ± 0.1 x 10
6
 13 ± 0.1 x 10
-3
 11 ± 1 
 25 1.10 ± 0.06 x 10
6 
19.2 ± 0.5 x 10
-3 
17.5 ± 0.4 
 30 1.1 ± 0.1 x 10
6
 31 ± 2 x 10
-3
 28 ± 2 
eIF4G (K
602
-F
622
) 10 1.8 ± 0.3 x 10
6
 18 ± 7 x 10
-3
 9.8 ± 0.7 
 15 1.7 ± 0.5 x 10
6 
22 ± 4 x 10
-3
 12 ± 2 
 20 1.7 ± 0.3 x 10
6
 35 ± 7 x 10
-3
 24 ± 4 
 25 1.7 ± 0.3 x 10
6 
48 ± 9 x 10
-3
 29 ± 6 
 30 2.00 ± 0.09 x 10
6
 100 ± 20 x 10
-3
 54 ± 11 
eIF4G (K
602
-F
620
), D
613
S, 
F
616
Q, F
620
L 
10 1.46 ± 0.04 x 10
6
 34 ± 4 x 10
-3
 23 ± 2 
15 2.3 ± 0.1 x 10
6 
70 ± 20 x 10
-3
 32 ± 7 
 20 2.6 ± 0.2 x 10
6
 147 ± 9 x 10
-3
 57 ± 1 
 25 2.0 ± 0.1 x 10
6 
120 ± 10 x 10
-3
 62 ± 6 
 30 2.0 ± 0.1 x 10
6
 177 ± 7 x 10
-3
 92 ± 6 
 
 
Table A2.2 – Kinetic binding data at a variety of salt concentrations for linear 
peptides determined by SPR. 
 [NaCl] (mM) Ka (M
-1
s
-1
) Kd (s
-1
) KD (nM) 
4E-BP1 (G
49
-N
64
) 225 0.9 ± 0.3 x 10
6
 23 ± 5 x 10
-3
 25 ± 6 
 500 0.8 ± 0.3 x 10
6 
55 ± 2 x 10
-3
 29 ± 1 
 1000 2.0 ± 0.4 x 10
6
 16 ± 7 x 10
-3
 8 ± 1 
4E-BP1 (R
51
-N
64
) 225 1.10 ± 0.06 x 10
6
 19.2 ± 0.5 x 10
-3
 17.5 ± 0.4 
 500 1.3 ± 0.3 x 10
6 
37 ± 6 x 10
-3 
34 ± 9 
 1000 1.2 ± 0.1 x 10
6
 86 ± 20 x 10
-3
 67 ± 9 
eIF4G (K
602
-F
622
) 225 1.7 ± 0.3 x 10
6
 46 ± 6 x 10
-3
 27 ± 5 
 500 2.7 ± 0.8 x 10
6 
150 ± 60 x 10
-3
 65 ± 4 
 1000 5.3 ± 0.1 x 10
6
 270 ± 70 x 10
-3
 51 ± 14 
eIF4G (K
602
-F
620
), D
613
S, 
F
616
Q, F
620
L 
225 2.0 ± 0.1 x 10
6
 123 ± 14 x 10
-3
 62 ± 6 
1000 0.15 ± 0.05 x 10
6 
2 ± 1 x 10
-3
 14 ± 3 
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4E-BP1 Linear Peptides 
4E-BP1 (G49-N64) 
30°C - 4E-BP1 (G49-N64) 
 
 
 
 
25°C - 4E-BP1 (G49-N64) 
 
87 
 
 
20°C - 4E-BP1 (G49-N64) 
 
15°C - 4E-BP1 (G49-N64) 
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10°C - 4E-BP1 (G49-N64) 
 
 
500 mM Sodium Chloride - 4E-BP1 (G49-N64) 
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1000 mM Sodium Chloride – 4EBP1 (G49-N64) 
 
 
4E-BP1 (R51-N64) 
30°C - 4E-BP1 (R51-N64) 
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25°C - 4E-BP1 (R51-N64) 
 
 
20°C - 4E-BP1 (R51-N64) 
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15°C - 4E-BP1 (R51-N64) 
 
 
10°C - 4E-BP1 (R51-N64) 
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500 mM Sodium Chloride - 4E-BP1 (R51-N64) – the instrument was experiencing a 
partial clog during these experiments.  Many curves needed to be removed due to 
spikes in the spectra, and the remaining curves are still quite ugly.  Therefore, the 
following sets of data need to be taken with a grain of salt (ha ha).  This data is not 
shown in the figure in the main text. 
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1000 mM Sodium Chloride - 4E-BP1 (R51-N64) 
 
 
eIF4G Linear Peptides 
eIF4G (K608-F622) 
30°C - eIF4G (K608-F622) 
 
94 
 
 
 
25°C - eIF4G (K608-F622) 
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20°C - eIF4G (K608-F622) 
 
 
15°C - eIF4G (K608-F622) 
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10°C - eIF4G (K608-F622) 
 
 
500 mM Sodium Chloride - eIF4G (K608-F622) 
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1000 mM Sodium Chloride - eIF4G (K608-F622) 
 
 
eIF4G (K608-F620) D613S, F616Q 
30°C - eIF4G (K608-F620) D613S, F616Q 
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25°C - eIF4G (K608-F620) D613S, F616Q 
 
 
20°C - eIF4G (K608-F620) D613S, F616Q 
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15°C - eIF4G (K608-F620) D613S, F616Q 
 
 
10°C - eIF4G (K608-F620) D613S, F616Q 
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1000 mM Sodium Chloride - eIF4G (K608-F620) D613S, F616Q 
 
Data for Other Peptides 
HCS-4E-BP1 
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HCS-eIF4G 
 
 
 
 
sTIP-04 
 
4E-BP1 (R51-N64) R51K, I52K, I53R 
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Appendix B 
Chapter 3 - Supplemental Information 
Compound Characterization 
All of the linear peptides were purchased through New England Peptide with the 
exception of 4E-BP1-10.  All peptides are acetylated on the amino terminus and 
amides on the carboxy terminus. 
4E-BP1-10 – Synthesized by Alyah Chmiel 
Sequence: GTRIIYDRKFLLECKN 
Mass Expected: 2009.09 
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mHCS-1 – Synthesized by Dr. James Song; characterization is in his thesis 
mHCS-2 
Sequence: GTRIIYDRXFLLXRRN; X = pentenyl glycine 
Mass Expected: 2055.99 
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mHCS-3 
Sequence: RIIYDRXFLMXCR; X = pentenyl glycine 
Mass Expected: 1747.94 
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mHCS-4 
Sequence: GTRIIYDRXFLNLXVRN; X = pentenyl glycine, NL = norleucine 
Mass Expected: 1998.15 
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mHCS-5 
Sequence: GTRIIYDRXFLNLXSRN; X = pentenyl glycine, NL = norleucine 
Mass Expected: 1986.12 
 
 
mHCS-6 
Sequence: RIIYSRXQLMXCRN; X = pentenyl glycine 
Mass Expected: 1814.98 
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mHCS-7 – Synthesized by Alyah Chmiel 
Sequence: RIIYDRXF*MXCRN; X = pentenyl glycine; * = cyclopropyl alanine 
Mass Expected: 1745.92 
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mHCS-8 – Synthesized by Alyah Chmiel 
Sequence: RIIYDRXF*MXCRN; X = pentenyl glycine; * = cyclobutyl alanine 
Mass Expected: 1759.94 
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mHCS-9 – Synthesized by Alyah Chmiel 
Sequence: RIIYDRXFL*XCRN; X = pentenyl glycine; * = O-methyl homoserine 
Mass Expected: 1731.96 
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mHCS-10 – Synthesized by Alyah Chmiel 
Mass Expected: 1761.95 
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OAlSer-1 
Sequence: GTRIIYDRXFLMXCRN; X = O-allyl serine 
Mass Expected: 2024.01 
 
 
HCS-1 – Synthesized by Dr. James Song; characterization is in his thesis 
HCS-2 – Synthesized by Dr. James Song, but purified by me 
Sequence: GTRIIYDRXFAAXCRN; X = pentenyl alanine 
Mass Expected: 1946.03 
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HCS-3 – Synthesized by Alyah Chmiel 
Sequence: KKRYDRXFLLXF; X = pentenyl alanine 
Mass Expected: 1675.99 
 
 
HCS-4 – Synthesized by Dr. James Song; characterization is in his thesis 
 
 
5x10
0
0.25
0.5
0.75
1
1.25
1.5
+ESI Scan (0.118-0.134 min, 3 Scans) Frag=225.0V AC1041 1-52.d  Subtract Deconvoluted  
1676.9985
1511.89671118.0007 1370.8155 2237.9952 2515.48631928.9271 2729.4805
Counts vs. Mass-to-Charge (m/z)
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LacA-1 – Synthesized separately by both Alyah Chmiel and me 
Sequence: RIIYDR(K)FLM(E)CR; (K) and (E) are cyclized 
Mass Expected: 1764.93 
 
 
 
 
 
 
 
 
115 
 
LacA-2 – Synthesized by Alyah Chmiel 
Sequence: RIIY*R(K)FLM(E)CR; (K) and (E) are cyclized; * = N-methyl aspartic acid 
Mass Expected: 1778.94 
 
 
LacB-1 – Synthesized separately by both Alyah Chmiel and me 
Sequence: RIIYDR(E)FLM(K)CR; (E) and (K) are cyclized 
Mass Expected: 1764.93 
 
5x10
0
0.5
1
1.5
2
2.5
+ESI Scan (0.139-0.172 min, 5 Scans) Frag=225.0V AC1077 1-26.d  Subtract Deconvoluted  
1779.9578
1615.8878 1952.94801243.6863 2450.2056 2719.39541062.5483 2228.4165
Counts vs. Mass-to-Charge (m/z)
900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 2100 2200 2300 2400 2500 2600 2700 2800
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LacB-2 
Sequence: RIIYSR(E)QLM(K)CRN; (E) and (K) are cyclized 
Mass Expected: 1831.97 
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The chloroalkane peptides had the following compound (abbreviated ct for 
chloroalkane tag) conjugated to their amino terminus. 
Cl
O
O
H
N
O
OH
O
 
LacA-1 Cl 
Sequence: ct-RIIYDR(K)FLM(E)CR; (K) and (E) are cyclized 
Mass Expected: 2028.06 
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LacB-1 Cl 
Sequence: ct-RIIYDR(E)FLM(K)CR; (E) and (K) are cyclized 
Mass Expected: 2028.06 
 
 
RRR-LacB-1 Cl 
Sequence: ct-RRRRIIYDR(E)FLM(K)CR; (E) and (K) are cyclized 
Mass Expected: 2496.36 
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LacB-2 Cl 
Sequence: ct-RIIYSR(E)QLM(K)CRN; (E) and (K) are cyclized 
Mass Expected: 2095.10 
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IC50 Curves for Peptides 
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CD Curves for Peptides 
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SPR Curves for Peptides 
4E-BP1-10 
 
mHCS-1 
 
mHCS-2 
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mHCS-3-E 
 
mHCS-3-L 
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mHCS-4 
 
mHCS-5 
 
mHCS-6-E 
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mHCS-6-L 
 
mHCS-7-E 
 
mHCS-7-L 
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mHCS-9-E 
 
mHCS-9-L 
 
mHCS-10-L 
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OAlSer-1 
 
 
LacA-1 
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